Indicate separate contributions of long-lived and short-lived greenhouse gases in emission targets | npj Climate and Atmospheric Science – Nature.com

To quantify the SR1.5 and AR6 statements quoted above, human-induced global temperature change over a multi-decade time-interval t, relative to the level of human-induced warming at the beginning of that interval (e.g. the present day or pre-industrial), can be decomposed using the framework articulated above as follows:

$${Delta} T = kappa _Eoverline {E_C} {Delta} t + kappa _Fleft( {{Delta} F_N + rho overline {F_N} {Delta} t} right),$$

(1)

where (overline {E_C}) and (overline {F_N}) are globally aggregated average CO2 emission-rates and non-CO2 radiative forcing, respectively (so (overline {E_C} {Delta} t) is cumulative CO2 emissions), and FN is the change in decadal-average non-CO2 forcing, all evaluated over that interval (the geophysical Zero Emissions Commitment is expected to be relatively small over a multi-decade time-interval23, but this may not be the case on longer timescales). The coefficients E (the TCRE) and F (the TCRF, or fast component of the climate response to any forcing change, denoted c1 in ref. 12, or sum of fast components24: see supplementary material), are both scenario-independent in the absence of strongly non-linear carbon cycle feedbacks or climate response. The only scenario-dependent coefficient is , the fractional Rate of Adjustment to Constant Forcing (RACF), or the relatively small fractional rate at which forcing needs to decline to maintain stable temperatures. It depends on how fast and how recently FN has increased (this term represents the delayed adjustment to past forcing increases, so is larger for more recent and rapid increases). If FN varies only on multi-decadal timescales, =c2/(Fs2), where c2 is the slow (multi-century) component of the climate sensitivity, and s2 the deep ocean thermal adjustment timescale. For representative12 coefficient values, 0.3% per year, making this third term usually small.

Aggregate CO2-e100 emissions cannot be used to calculate FN if these comprise a mixture of LLCFs and SLCFs. Aggregate CO2-e100 emissions of LLCFs, EL, can, however, be combined unambiguously and have the same impact on global temperature on decade to century timescales as the corresponding quantity of CO2. Likewise, aggregate CO2-e100 emissions of SLCFs, ES, multiplied by the AGWP100 of CO2, A100, give SLCF radiative forcing, FS (A100 normally includes a first-order estimate of the impact of carbon cycle feedbacks25 so, for consistency, this should also be included in the GWP100 values used to compute ES).

For emissions reported as CO2-e100 the above expression can therefore be re-written (now grouping all LLCFs with CO2):

$${Delta} T = kappa _Eoverline {E_L} {Delta} t + kappa _Fleft( {{Delta} F_S + rho overline {F_S} {Delta} t} right),$$

(2)

or equivalently, using FS=A100ES on multi-decadal timescales,

$${Delta} T = kappa _Eoverline {E_L} {Delta} t + kappa _FA_{100}left( {{Delta} E_S + rho overline {E_S} {Delta} t} right).$$

(3)

Hence T can be estimated directly using well-known (albeit uncertain) climate system properties if, and only if, total CO2-e100 emissions of long-lived climate forcers, EL, are specified in emission targets together with total CO2-e100 emissions, EL+ES; or, equivalently, EL and ES are specified separately. T cannot be calculated from the sum of EL+ES alone.

This is illustrated by Fig. 1, which shows the impact of LLCF and SLCF emissions, expressed as CO2-e100, on global temperature change over a multi-decade period, relative to the level of warming at the beginning of that period, calculated with a simple climate model12. Stylised cases of constant (darker shades) and step-change (+10%, lighter shades, and 50%, dotted lines) emissions are shown in panels a and c. Warming due to LLCF emissions (the term (kappa _Eoverline {E_L} {Delta} t) in Eq. (3)) increases linearly with cumulative emissions in all three cases (panel b). Warming due to an ongoing constant emission of an SLCF that started decades before the beginning of this period (the (kappa _FA_{100}rho overline {E_S} {Delta} t) term) also increases linearly (panel d, darker blue) but at a slower rate per tCO2-e100 emitted (by a factor of about 4, because E4FA100): global temperatures have already partially equilibrated with this constant emission (by how much depends on how long ago these SLCF emissions began, which is why is the only scenario-dependent coefficient in these expressions). Finally, warming due to an increase in SLCF emissions (the FA100ES term, panel d, lighter blue) is 45 times greater than would be expected from the same increase in tCO2-e100 emissions of an LLCF (panel b, lighter red) over the 20 years following the increase (FA1004.5E20 years). Hence the AR6 statement expressing methane emissions as CO2 equivalent emissions using GWP100 overstates the effect of constant methane emissions on global surface temperature by a factor of 34 while understating the effect of any new methane emission source by a factor of 45 over the 20 years following the introduction of the new source26 applies to the impact of global emissions of any SLCF. Any decrease in SLCF emissions also has a much greater impact on temperatures over a multi-decade period per tCO2-e100 avoided than a corresponding decrease in LLCF emissions (red and blue dotted lines) (Fig. 1).

Darker bands in panels a and c show, respectively, constant LLCF and SLCF emissions of 1 tCO2-e100 per year starting some decades before the interval shown. Pale bands show a 10% increase one-quarter of the way through the interval shown, while dotted lines show a 50% decrease. Resulting temperature changes relative to the start of this interval shown in panels b and d, calculated using a simple climate model: vertical axes in b and d are scaled identically to illustrate smaller rate of warming due to constant SLCF emissions and much larger warming impact of any change in SLCF emissions relative to the warming due to identical CO2-e100 LLCF emissions. Vertical arrows in the right show predicted contributions to T from the individual terms in Eq. (3): three arrows in panel b show cumulative LLCF emissions over this interval multiplied by the TCRE for the three scenarios shown; the lower and upper arrows in panel d show, respectively, the predicted warming due to ongoing constant SLCF emissions and additional warming due to the 10% increase. The figure illustrates that Eq. (3) allows reliable, if approximate, prediction of multi-decade warming T if, and only if, LLCF and SLCF emissions are specified separately.

Temperature changes in the figure are calculated using a particular model, LLCF, SLCF and scenario. The figure would, however, appear similar if another model, combination of gases or scenario of prior emissions were used, provided emissions do not change rapidly immediately before the beginning or end of the period shown, because the relationship between emissions and warming expressed in Eq. (3) is generic. Individual terms in Eq. (3), assuming constant coefficients, are shown by the arrows on the right of panels b and d. These match the warming calculated by the explicit simple climate model within modelling uncertainties. The figure shows temperature change relative to the start of the period rather than absolute warming because the latter is not determined by Eq. (3) but depends on the prior LLCF and SLCF emissions history (the specific scenario used to generate this figure is shown in full in the Supplementary Information).

Temperature change T over a multi-decade period depends, to first order, only on cumulative emissions of LLCFs (overline {E_L} {Delta} t), cumulative emissions of SLCFs (overline {E_S} {Delta} t), and net change in total SLCF emission rates ES, over that period alone. As the SR1.5 and AR6 emphasised, future warming depends on future emissions. Making use of this information, however, requires both EL and ES to be specified: only specifying the sum EL+ES introduces an ambiguity in temperature outcome.

Separate specification also facilitates assessing the implications of different metrics. For example, aggregate CO2-equivalent emissions using the 20-year Global Warming Potential (GWP20) can be approximated by EL+3ES if both EL and ES are reported as CO2-e100, with a slightly higher multiplicative factor (up to 4) if ES is dominated by forcers with lifetimes of order one year (Table 8.A.1 of ref. 12 shows that GWP20 values are similar to GWP100 values for LLCFs and 3 or 4 times GWP100 values for gases with lifetimes of order a decade or a year, respectively). Finally, we re-emphasise that these expressions capture our physical understanding of how global emissions of LLCFs and SLCFs collectively determine global temperature change, and illustrate the utility of separate specification of EL and ES. How this understanding is used to inform the assessment of the adequacy of individual emission targets depends on other considerations listed above and cannot be argued from a physical science perspective alone. There will be several other advantages to the additional communication such as being able to estimate air quality co-benefits of mitigation.

Continued here:
Indicate separate contributions of long-lived and short-lived greenhouse gases in emission targets | npj Climate and Atmospheric Science - Nature.com

Gender, health and racial inequalities to be tackled in flagship Ferring grant programme – Financial Post

Breadcrumb Trail Links

Author of the article:

SAINT-PREX, Switzerland Forensic analysis of stone age human fertility to better understand why modern-day sperm counts are falling, and a project to support safe birth in rural Ethiopia by providing trained midwives and solar power kits, are among 17 winners of a new Ferring Pharmaceuticals grant programme unveiled today.

This advertisement has not loaded yet, but your article continues below.

The wide-ranging programme is designed to tackle inequalities and disparities in reproductive medicine and maternal health, reinforcing Ferrings ambitious #ProjectFamily Commitment , which supports everyones right to build families of every shape and size.

Through collaboration with people across the globe, Ferring has outlined how it will develop programs, services, and treatments to address unmet needs in reproductive medicine and maternal health. Millions of people around the world are unable to access the care, treatment and support they need to build a family, and so, the grants aim to support projects that focus on delivering better outcomes and solutions at every stage of the reproductive journey, from conception to birth.

At Ferring, we believe in everyones right to a family. That is why we are determined to play our part in collaborating to tackle some of the unique challenges faced by people across the globe when building families, said Per Falk, President of Ferring Pharmaceuticals. The projects funded by the grant programme aim to address some of the greatest global gender, health and racial inequalities in reproductive medicine and we look forward to realising positive outcomes of these projects.

Todays announcement totals funding of nearly 2.9 million to support 17 projects in nine countries, including Australia, Brazil, Canada, Denmark, Ethiopia, South Sudan, Uganda, the United Kingdom and the United States. It includes the 12 inaugural winners of the Racial Equality Grants in Reproductive Medicine and Maternal Health, a dedicated research programme to deepen understanding and drive solutions to tackle racial disparities in reproductive medicine and maternal health. The programme comprehensively addresses the scope of this issue by funding innovative research proposals in epidemiology as well as basic, clinical, translational, and social sciences.

The programme builds on the success of # ProjectFamily: Safe Birth initiative, a decade-long public-private partnership, which earlier this year introduced a heat-stable formulation to prevent excessive bleeding after childbirth, known as postpartum haemorrhage (PPH). By seeking to prevent PPH, Ferring will support efforts to protect the lives of 20 million women and their families by 2030.

How the grants programme aligns to the Ferring #ProjectFamily Commitment:

This advertisement has not loaded yet, but your article continues below.

#1 Learning from patients to improve their treatment and care

Key fact: Cancer treatments can reduce the chances of having a family, so fertility preservation interventions need to happen before treatment starts. 1 Decisions regarding the potential risk to fertility therefore need to be made with extreme time pressure when the person is also dealing with the new cancer diagnosis. A recent UK survey highlighted problems in accessing fertility preservation for young cancer patients. 2

Research grant: University of Edinburgh Development Trust and University Court of the University of Edinburgh and its research project, Supporting Fertility Preservation Treatment Decision-Making. This project will develop fertility preservation patient decision making aids to support cancer patients across Europe. This study will build on an existing web-based decision aid created by the research team and will create new tailored resources for different patient groups in a range of languages.

#2 Collaborating to reduce maternal and infant mortality

Key fact: In rural Ethiopia, unreliable or non-existent power supplies mean that women delivering at night may give birth in the dark, preventing midwives being able to detect or manage complications. Training midwives and providing safer birthing conditions by supplying light and reliable power is critical to addressing this.

Support grant: Ferring is supporting GreenLamp, an organisation dedicated to improving conditions for mothers and babies in rural Ethiopia and its Ethiopian Maternal Health Community Programme through a 5-year holistic model, which will lead to high impact and sustainable improvements in a region of rural Ethiopia with extreme unmet needs.

Key fact: Every year, 70,000 women die from PPH, 3 with the majority of deaths occurring in low- and lower-middle income countries. 4 The majority of PPH deaths could be avoided through preventative approaches, however, this is not always the reality for those living in humanitarian crisis settings, for example conflict regions, natural disasters and public health emergencies.

Research grant: The United Nations Population Fund (UNFPA) is collaborating with Ferring Pharmaceuticals to contribute to the body of evidence regarding the safe introduction of additional resources such as heat-stable carbetocin for the prevention of PPH in low resource humanitarian contexts such as Uganda and South Sudan. Through this, both organisations aim to contribute to providing access to safe birth in the most vulnerable settings.

This advertisement has not loaded yet, but your article continues below.

#3 Closing gender and racial inequality gaps in reproductive medicine and maternal health

Key fact: Around the world, including in high income countries, black women and women of colour are more likely to die from complications during pregnancy and childbirth than white women. Startling racial disparities also exist in fertility treatment. Studies in the US suggest that black women may be twice as likely as white women to have fertility problems but are far less likely to seek or receive treatment that could help them to build their families. 5 Furthermore, in the UK, minority ethnic groups undergoing fertility treatment are less likely to have a baby, with black couples having the lowest chance of successful treatment. 6

Research grant: The Ferring Innovation Grants Programme for Racial Equality in Reproductive Medicine and Maternal Health, a dedicated research programme to deepen understanding and, ultimately, drive solutions to tackle racial disparities in reproductive medicine and maternal health, including maternal mortality, in-vitro fertilisation (IVF), pregnancy and postpartum outcomes.

#4 Working together to win hearts and minds

Key fact: The fertility rate the average number of children a woman gives birth to is falling. If the number falls below approximately 2.1, then the size of the population starts to decrease. In 1950, women were having an average of 4.7 children in their lifetime. Research showed the global fertility rate nearly halved to 2.4 in 2017 and projections indicate it will fall below 1.7 by 2100. 7 In line with this, the number of babies born globally as a result of IVF increased from under one million in 2007, to over two million in 2012. 8

Research grant: International Federation of Fertility Societies (IFFS) and its research project, Global decreasing fecundity trends: Society changes and implications, fertility awareness and access to infertility care.

Research grant: Globe institute at the University of Copenhagen and Copenhagen University Hospital Rigshospitalet research project, Understanding the reproduction paradigm of humankind in the Anthropocene (Ancient Reproduction) which aims to map the evolutionary history of reproductive dysfunction by evaluating changes in environmental pollution and associated biological responses over time.

ENDS

About the Ferring Innovation Grants Programme for Racial Equality in Reproductive Medicine and Maternal Health The Ferring Innovation Grants Programme for Racial Equality in Reproductive Medicine and Maternal Health (RMMH) aims to fund projects to deepen understanding and, ultimately, drive solutions to tackle racial disparities in RMMH, including maternal mortality, in-vitro fertilisation (IVF), pregnancy and postpartum outcomes.

This advertisement has not loaded yet, but your article continues below.

The Ferring Innovation Grants Programme for Racial Equality in RMMH provides research grants of up to 20,000 and aims to fund multidisciplinary research projects across four main areas: basic and translational; clinical; epidemiology and prevention; and social science research. The winners for 2021 included Monash University (Australia), Universidade Federal de Minas Gerais (Brazil), McMaster University (Canada), University of Copenhagen (Denmark), Boston IVF Fertility Clinic (USA), Boston University (USA), Foundation for Research and Education Excellence (USA), Johns Hopkins University (USA), Rejuvenating Fertility Center (USA) and Yale School of Medicine (USA).

About Ferring Pharmaceuticals Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,000 people worldwide, has its own operating subsidiaries in more than 50 countries and markets its products in 110 countries.

Learn more at http://www.ferring.com , or connect with us on Twitter , Facebook , Instagram , LinkedIn and YouTube .

# # #

1 Anderson RA, et al. The impact of cancer on subsequent chance of pregnancy: a population-based analysis. Hum Reprod 2018;33: 1281-1290. 2 Newton HL, Picton HM, Friend AJ, et al. Inconsistencies in fertility preservation for young people with cancer in the UK Archives of Disease in Childhood Published Online First: 20 September 2021. doi:10.1136/archdischild-2021-321873 3 World Health Organization. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: https://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed January 2022. 4 Say L, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health. 2014; 2 (6):e323-33. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed January 2022. 5 STAT. For black women, the isolation of infertility is compounded by barriers to treatment Available at: https://www.statnews.com/2020/10/14/for-black-women-isolation-of-infertility-compounded-by-barriers-to-treatment/ Last accessed January 2022. 6 Human Fertilisation & Embryology Authority (HFEA). UK ethnicity statistics for IVF and DI fertility treatment. Available at: https://www.hfea.gov.uk/about-us/publications/research-and-data/ethnic-diversity-in-fertility-treatment-2018/ Last accessed January 2022. 7 BBC News. Fertility rate: Jaw-dropping global crash in children being born Available at: https://www.bbc.co.uk/news/health-53409521 Last accessed January 2022. 8 American Society for Reproductive Medicine (ASRM). The number of babies born globally after treatment with the assisted reproductive technologies (ART). Available at: https://www.fertstert.org/article/S0015-0282(13)02586-7/fulltext#relatedArticles Last accessed January 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005619/en/

Contacts

Danielle Forrester Associate Director, 90TEN +44 75 9120 0047 (mobile) ferring@90ten.co.uk

Bhavin Vaid Head of Corporate Communications +41 79 191 0632 (mobile) bhavin.vaid@ferring.com

#distro

This advertisement has not loaded yet, but your article continues below.

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

A welcome email is on its way. If you don't see it, please check your junk folder.

The next issue of Financial Post Top Stories will soon be in your inbox.

We encountered an issue signing you up. Please try again

Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notificationsyou will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.

Original post:
Gender, health and racial inequalities to be tackled in flagship Ferring grant programme - Financial Post

COVID antivirals effective – if you can get them – Newnan Times-Herald

While new medications are available to treat COVID-19, they can be hard to come by and most definitely aren't for everyone.

They also need to be taken early in the disease to be most effective; oral antivirals must be started within five days of symptoms, while IV medications, which are even more scarce, can be taken within the first 10 days.

There are four currently approved therapeutics for those in the early days of COVID-19 who aren't hospitalized or requiring oxygen because of COVID-19, but are at high risk for severe COVID-19.

They are the oral antivirals Paxlovid and molnupiravir, the monoclonal antibody treatment sotrovimab, and the IV antiviral remdesivir.

The state of Georgia is distributing Paxlovid and molnupiravir through certain pharmacies. In Coweta, the only location is Walgreens at 3116 Highway 34 East.

Paxlovid, which is considered the first choice for those who are eligible, is much more scarce than molnupiravir.

Both medications received emergency use authorization from the FDA in late December, and production has not yet ramped up to reach the demand.

Paxlovid was found to be dramatically more effective in clinical trials than molnupiravir, though it is contraindicated in patients with severe liver or kidney disease and carries several drug interaction precautions. Clinical trials found it to reduce the risk of COVID-19 hospitalization or death by 89 percent, according to Pfizer. Patients may be able to discontinue some of their other medications while taking Paxlovid to avoid the interactions, in consultation with their physician.

Molnupiravir was found to be 30 percent effective and, under its EUA, should only be used if a patient is unable to obtain Paxlovid, sotrovimab or remdesivir.

On Friday, the U.S. Department of Health and Human Services COVID-19 Locater showed 11 courses of Paxlovid available at the local Walgreens, out of an initial allotment of 180. There were 374 courses of molnupiravir out of an initial allotment of 700.

As of Friday, there were only 56,604 courses of Paxlovid available in the entire country, according to the U.S. Department of Health and Human Services COVID-19 Locator. That's out of a total allotment of 194,700. Molnupiravir is much more abundant, with 361,035 courses out of a total of 660,280.

Monoclonal antibodies extremely scarce

Sotrovimab, the only monoclonal antibody treatment shown to be effective against the Omicron variant, doesn't appear to be available locally, but is offered at some Wellstar Health System locations.

The HHS shows that Georgia received 1,296 courses of Sotrovimab this week and 1,548 courses last week.

The monoclonal antibodies that were used frequently to treat the Delta variant, including REGEN-COV, are not effective against the currently circulating Omicron variant, and are no longer available.

There is also a monoclonal antibody product that is used for those who are severely immunocompromised to help keep them from getting COVID-19 in the first place. Evusheld is for "pre-exposure prophylaxis for those who either cannot receive a COVID-19 vaccine or who have a moderate to severe immune condition that may prevent them from mounting an adequate immune response to COVID-19 vaccination. It is only for patients who have not had a recent exposure to someone with COVID-19.

According to the HHS locator, Cancer Treatment Centers of America in Newnan received 24 courses of Evusheld in late December and lists no courses available. Some hospitals in the Atlanta-area also received Evusheld. While most no longer have it, some locations do have it available.

Antivirals not for everyone

When it comes to the oral antivirals, women and men of childbearing age must be careful if taking molnupiravir. It is not recommended for use in pregnancy and those taking it should use a reliable form of birth control while taking it and for four days afterward, according to the emergency use authorization. However, pregnant women at high risk "may reasonably choose molnupiravir therapy after being fully informed of the risks," particularly if they are more than 10 week pregnant, according to the National Institutes of Health. Men who are sexually active with women of child bearing age are asked to use a reliable form of birth control while taking it and for three months afterward.

While Paxlovid was approved unanimously by an FDA advisory panel, molnupiravir was approved by a vote of 13-10.

The two medications have different mechanisms of action. Molnupiravir stops the virus by introducing mutations as it tries to reproduce, shutting down reproduction. Paxlovid is a main protease inhibitor, which prevents the virus from making the proteins it needs to grow.

Some researchers have expressed concerns molnupiravir mechanism of action could lead to the rise of new COVID-19 variants, according to the journal Nature.

This could become an issue if someone doesn't take the full five day course and doesn't completely clear the virus, Sankar Swaminathan, the division chief for infectious diseases at the University of Utah Health in Salt Lake City and a member of the FDA advisory panel, told Nature. Swaminathan voted against the EUA for molnupiravir.

Nicholas Kartsonis, the senior vice-president of clinical research at Merck, said that no remaining virus was detected in the trial participants after the full five day course, according to Nature; however, the medication was not tested in immunocompromised people, who may have trouble clearing the virus.

The FDA is requiring Merck to establish a process to monitor for the emergency of variants.

There are also concerns that the drug could cause mutations in DNA, but animal studies indicated that the risk is low, according to Nature. However, that risk is the reason for the pregnancy and birth control recommendations, and why the medication is not approved for those under 18.

Other than that, there are no contraindications such as those with Paxlovid, and no drug interactions.

My symptoms all faded away

Molnupiravir worked dramatically well for Cowetan Kim Kramer, who tested positive for COVID-19 on Jan. 3.

Kramer, 62, has heart failure, which puts her at high risk for severe COVID-19. When she woke up feeling bad after her husband had contracted COVID-19, she took an at-home test and it was strongly positive.

Because of the heart failure, she knew she needed to let her doctor, Erika Martinez-Uribe, know, even on a Sunday. Though Kramer is vaccinated, her condition puts her at high risk.

Kramer had heard about the antivirals being approved, and her doctor asked if she would be willing to try molnupiravir.

"I said yes, because I completely trust Dr. Martinez," Kramer said. Her husband was able to pick the medication up the next day at Walgreens, even though she usually gets her medications elsewhere.

She took the first dose that night, and the second dose the next morning. By that afternoon, "I started to feel much better," Kramer said. By that night, my symptoms all faded away, and I didn't have any more symptoms ever again."

Her symptoms hadn't been severe, but she and her doctor wanted to make sure they didn't get that way.

"I didn't want to end up in the hospital," Kramer said. Heart failure can really exacerbate COVID-19 symptoms, she said. "It makes it so much worse."

Martinez-Uribe happened to be on call that Sunday, instead of one of her colleges. She had heard about the antivirals being approved and knew that they had to be given as soon as possible. But finding them was going to be the issue. There was less information about finding the medications than there is now.

"I was trying to figure out how to get this medicine. I had to research this on my own," she said. She had heard someone say they heard Walgreens had it. "It was like a rumor," she said.

She called and the pharmacist said they had some molnupiravir, but no Paxlovid. Martinez-Uribe did some research on the medication and then called in the prescription.

She said she has prescribed the antivirals for a handful of patients, all around the same time, and most have done very well with it, though one was still feeling bad after taking it but the patient recovered without incident.

She's had a lot more patients ask for it.

Martinez-Uribe said she had one patient who was in their mid 30s, vaccinated, with no underlying conditions.

She had to tell the patient she was sorry, but that they didn't qualify for the medication. She continues to encourage people to be vaccinated against COVID-19.

She said some of her colleagues, who have a lot of older patients with chronic medical conditions, have been prescribing it a lot.

"I have to take each case by case," Martinez-Uribe said. "These medicines, at this moment, are not for everyone." Instead, they are only for people with conditions that could cause them to have severe cases of COVID-19. "That is how we need to be using them," she said at least while they are so scarce. With more data and greater supply, maybe well expand to be able to provide it for our regular patients, she said. Right now were trying to focus on the high risk.

To see availability of Paxlovid and molnupiravir, visit https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/ .

Continued here:
COVID antivirals effective - if you can get them - Newnan Times-Herald

China’s plan for Xinjiang, plus what’s lurking in your household dust? The Conversation Weekly podcast transcript – The Conversation UK

This is a transcript of The Conversation Weekly podcast episde: Chinas plans for Xinjiang, and what it means for the regions persecuted Uyghurs, published on January 27, 2022.

NOTE: Transcripts may contain errors. Please check the corresponding audio before quoting in print.

Dan Merino: Hello, and welcome to The Conversation Weekly.

Gemma Ware: This week, three experts explain Chinas long-term vision for Xinjiang, and what it means for the regions persecuted Uyghurs.

David Tobin: The underlying problem is the notion that Uyghurs were barbarians and became human by becoming Chinese in 1949.

Anna Hayes: Xi Jinpings bigger goal here is the China dream.

Dan: And, what toxic heavy metals are lingering in houses around the world? We talk to a researcher who gets dust from thousands of vacuum cleaners mailed to them and tests that dust for safety.

Cynthia Isley: Theyre present in higher concentrations in homes than we would find outdoors.

Gemma: Im Gemma Ware in London.

Dan: And Im Dan Merino in San Francisco. Youre listening to The Conversation Weekly: the world explained by experts.

Gemma: Whats the latest communication that youve had with somebody inside Xinjiang, and what did they say?

Darren Byler: Well, its difficult to access Uyghur folks directly because of the surveillance system. So much of the information I get comes through Uyghurs who are contacting their family members in the region and them telling them about whats happened to their families, whats happened.

Gemma: This is Darren Byler. Hes an anthropologist who researches northwest China, and hes based at Simon Fraser University in British Columbia in Canada.

Darren: Also conversations that I have with Han people, which are not Uyghurs, but have much more freedom to speak openly with people abroad. And so, you know, Ive talked to people who have been there in the last few months and have talked about how some of the most violent and, sort of, stressful aspects of the system have begun to dissipate or have been pushed to the side in some ways. That theres less people that are being detained at the moment than there were just like a year or two ago. Some of the older folks, you know, people that were in ill health have been returned to their neighbourhoods and are kind of on watch lists and are being monitored. But still theres widespread family separation, hundreds of thousands of people are still missing. And so the situation continues even as it is sort of normalised in some ways.

Gemma: What different methods are the Chinese government using to persecute Uyghurs?

Darren: Well, I think we could probably put them in a few different categories. Theres targeting of people in terms of political framing of Uyghurs as potentially terrorists. Theyre controlling people using biometrics; their faces, their fingerprints. Theres ways that theyre tracking peoples reproduction. Theyre also using technological systems to go through peoples digital history and track them over time. And then of course, theyre using forms of cultural control, stopping people from producing Uyghur knowledge, from using Uyghur language. Theyre criminalising immense aspects of what it means to be Uyghur itself.

Read more: I researched Uighur society in China for 8 years and watched how technology opened new opportunities then became a trap

Newsclip: The Biden administration will not send any diplomatic or official representation to the Beijing 2022 Winter Olympics given the PRCs ongoing genocide and crimes against humanity in Xinjiang.

Dan: In December, the United States announced a diplomatic boycott of the Beijing Winter Olympics, due to begin on February 4.

Gemma: The UK, Australia, and Canada soon followed suit.

Dan: The boycotts are limited. Diplomats from those countries will not attend the winter games, but the athletes will still compete.

Gemma: Also in December, the Uyghur Tribunal an independent, unofficial tribunal based in London found China guilty of crimes against humanity and genocide against the Uyghurs.

Newsclip: Hundreds of thousands of Uyghurs have been detained by PRC authorities without any or any remotely sufficient reason.

Dan: All the while, China has continued to deny allegations of genocide and human rights abuses in Xinjiang, rejecting these claims as absurd.

Newsclip: China has slammed a United Nations declaration that accuses Beijing of human rights abuses.

Gemma: Ive been talking to three experts whove carried out research in Xinjiang, to understand whats happening to Uyghurs and the other Muslim minorities who live there.

Its hard to get the full picture of how many people have been taken into camps in Xinjiang. Estimates range from one to two million. I asked Darren Byler what figure he thinks is the most accurate.

Darren: What I see in the internal police documents is that, you know, something between 10% to 20% of the people adult Muslim population have been taken. So, the numbers you just cited are within that range.

Gemma: What is life like in these camps from the information that youve been able to gain from your research?

Darren: What typically happens in the camps is people are put into these cells that are locked. Theyre basically a medium security prison cell, which has bunk beds and have ten to 30 people within them. During the day theyre often asked to sit on plastic stools for many hours at a time and watch TV shows on this flat-screen TV thats up on the wall, which are, you know, Chinese language instruction, and how to sing patriotic songs.

Theyre being watched through a camera system at all times, the lights are not turned off. Theres just so much control, a lot of it automated through the surveillance system. You know, theyll receive a command through a speaker system if they get up from the stools or if they cover their face while theyre sleeping. So its really using this kind of cutting-edge smart technology to control bodily movement throughout every aspect of their day, and I think that more than anything really wears people down.

And then of course, they also see the guards beating people as they escort people throughout the camp.

Gemma: China calls these re-education camps, and thereve been variously termed internment camps, concentration camps. Is there any sense of what do you need to do in order to leave?

Darrem: The state refers to them as closed, concentrated education and training centres. The way you progress out of the camps is you need to pass language exams, you need to pass ideology exams. Theres a point system that they use at times, which has to do with good conduct. But many former detainees told me that it was actually really arbitrary, in terms of how you got out. Mostly it had to do with a factory needing workers that was being built nearby, and so, you know, once the factory was ready, then they would transfer people out. So it really seemed to have more of an economic logic, and the workers being able bodied, as to whether people were transferred.

Gemma: And its mainly men in these camps?

Darren: I would say about two thirds of the people that are detained or are men, and most are between the ages of 15 and 55, but there are women that are held as well. Theres a disproportionate number of people that were transferred from the camps to factories that were women. Many of the people that were sent to prison were men.

Gemma: And what do we know about whether people have died in the camps?

Darren: We dont have systematic data in terms of how many people have died. Many of the people I interviewed who were in the camps as detainees talked about seeing people that appear to be on the brink of death in their cells being taken away, some witnessed suicides. It seems like most of the deaths had to do with neglect, with being in ill health, with lack of hygiene and lack of healthcare in in the camps. And then you know, when COVID hit, we were concerned that that could spread and become systematic throughout the camps as well. It doesnt appear that that happened.

Gemma: You said youve been told by Uyghurs that fewer people are being taken into the camps. So whats happening now?

Darren: Well, what weve seen is that a number of camps have simply been turned into formal detention centres. So kanshousuo in Chinese, which is really the term that in the United States they would use for jails. And so its part of the formal incarceration system and, you know, in the Chinese case, most people that are held there are held as theyre awaiting trial. So a number of camps have just simply become these pre-trial centres. Other camps have been closed, abandoned. But in still other cases, theyve actually been turned into factories themselves. And so it does appear as though the state was maybe acting more reactively to international pressure and wanting to close them more quickly than they were at least intending at the outset. It isnt clear what the future holds, but you know, it seems as though factories and prisons are mostly the direction theyre headed in.

Gemma: And from the conversations youve had with former detainees whove come out, did they absorb what they were being told? Do they feel that they learned anything?

Darren: I asked that question to a whole bunch of them as part of my interview to sort of chart that, and most said that they didnt learn anything when it came to Chinese language or even ideology, really. I mean, they learned enough to pass some exams. They memorised some characters, many of them said that theyd memorised 33 or 40 different songs. But in terms of, like, Chinese language fluency, and even understanding of Chinese law, that wasnt really clear to them.

Really, what they learned was how to be submissive, how to understand their place as sort of really a criminal class. The guards would call them animals, so they understood that they were be being treated as subhuman and that they should sort of recognise themselves as that. So theres, you know, a lot of shame, a lot of trauma that they carry with them.

People would tell me that the worst thing they felt was when they came out of the camp, having to denounce their past behaviour and other people that they knew in front of their community, and then being treated as an outcast. Once youre transferred out, then you have to do the work that youre assigned to do. Youre still being watched really closely. You cant ask about the pay that you are, or arent, given.

Gemma: So weve talked about what lifes been like in the camps. Whats life like outside the camps?

Darren: So for people that werent detained, many of them had family members or people in their community who were detained. And so the status coercion was placed across the entire population of Muslim people, meaning that they could at any time be determined to be untrustworthy and taken to the camp.

The lines in terms of who is trustworthy or not are very porous and arbitrary, really depends on which official youre talking to, which device is scanning your phone, and so that meant that everyone was terrified really by that threat. And the surveillance system really worked to exacerbate and amplify that terror and that part is ongoing. Theres checkpoints at jurisdictional boundaries where people have their face scanned and match the image on their ID. They often have their phone scanned at the same spot. If youre on a watch list because you have a family member in the camp, you have people coming into your home to visit you and inspect your home, looking through your things to make sure you dont have any religious materials. Theyre testing you, you know, making you drink alcohol to prove that youre not a pious Muslim. Theyre asking your children to report things that youre doing as a parent. Its so invasive. Its in all aspects of life. People talked about that system as one that was suffocating. That they felt like even though they werent in the camp, they were still within a sort of open air prison.

Gemma: What do your interviewees tell you about their thoughts about the future and how they see it for themselves in Xinjiang?

Darren: So, you know, I think people now feel as though if they havent been sent to the camp or imprisoned taken yet that theyre probably fine. I think thats becoming something of a widespread feeling. This is based on interviews Ive done with people whove travelled to the region recently.

But at the same time, they know that anyone can still be taken. It just doesnt feel quite as imminent of a threat. So I guess in the short term, theres been a little bit of a relaxation. I think the deeper trauma of family separation, of forced birth control you know, ranging from sterilisation to other forms of long term birth control that continues as well. The surveillance system is still there. You know, theres a lot of anxious people still.

The children, I think, are the ones that we should be most concerned with because theyre being raised in this residential boarding school system, really separated from their parents and from the culture that they came from. Its really producing a lost generation of Uyghurs who will be dealing with the fallout of whats happened to them for the rest of their lives.

So thats the future, its quite bleak I would say. Theyre alive and, you know, it seems like the threat of mass death is now less imminent than it mightve been in the past. That was a lot of concern that we had when the camps were first built is that people could simply be killed. Now, it seems like the state is sort of taking a more middle position, is being a little less aggressive when it comes to crimes against humanity.

Gemma: Why would China want to erase Uyghur culture, language, and future generations? To understand that, we need to understand the history of the region Uyghurs call home, and the way its been viewed by the rest of China.

David Tobin: The underlying problem in how Xinjiang is is governed in China is the notion that Uyghurs were barbarians and became human by becoming Chinese in 1949.

Gemma: This is David Tobin, a lecturer in East Asian studies at the University of Sheffield in the UK.

David: My research focuses on identity and security in global politics, with the focus on Han-Uyghur relations in the Xinjiang Uyghur Autonomous Region.

Gemma: Now, the Xinjiang Uyghur Autonomous Region is what this region is called today. But it hasnt always been called that, and its not always even been a part of China. So, give us a brief history of this place.

David: A brief crash course in Xinjiang history would start with the name East Turkestan. This tends to be the name that Uyghurs use. Turkestan just means land of the Turks. Turk includes, Uyghurs, Kazakhs, Kyrgyz, so theres a multi-ethnic component to it. So the term today is usually seen as a loose geographical meaning, meaning that its just part of central Asia in the east, that borders China. The region is not seen as culturally Chinese. Uyghurs speak a Turkic language, a different language family from Mandarin, and generally practice Islam.

It was never seen as part of the Chinese nation. It was a colony. It wasnt called Xinjiang until 1884. The region was actually unified by the Manchu. Historically the region wasnt usually ruled by one ruler, there were different kingdoms. So it became to be seen as Xinjiang rather than these different states.

So this gave us a new language to Uyghur nationalists, who then by the 30s and 40s established independent East Turkestan republics based on their identity as Turkic speakers, as practitioners of Islam. The region is really ruled by custom until 1949, so local leaders were largely kept in place. But this obviously changed with China starting to see itself as a nation state, not just a nation or a civilisation, but saying the borders of China should reflect our national identity.

So, in 1949, when the Peoples Liberation Army arrive in Urumchi, this is called a peaceful liberation. Its a bit of a paradox. In the Chinese narrative its always been part of China, yet we have to keep liberating the region because in practice, it wasnt seen as part of the Chinese nation by Chinese people or by Uyghurs.

Gemma: In 1949, when the region became officially part of the Peoples Republic of China, what was its ethnic and religious makeup at that point?

David: In 1949, the population of Xinjiang was approximately 5% Han. And now today the population is around 50% Han, though official statistics do vary. So the transformation since 1949 has been dramatic, particularly when we think about language. In 1949 and in rural Xinjiang, Uyghur language is the lingua franca. Its intelligible with Kazakh and Kyrgyz. And at that stage in 1949, Han Chinese people would have had to learn to speak some Uyghur to be able to communicate with people. This is obviously now not the case.

Gemma: Did anything change in the way Uyghurs were viewed by the Chinese state when The Chinese Communist Party and Mao Zedong came to power in 1949?

David: Uyghurs were traditionally called barbarians by the Chinese state. In imperial history of China, you had the centre of civilisation in Beijing or where the capital was and as you get further from the centre, the peoples become more barbaric, less cooked and more raw as the terminology says.

But when Mao Zedong comes to power, hes saying China shouldnt be chauvinist. China shouldnt be ethno-nationalist. It must be multi-cultural, it must find a new way to include minorities. So he said we shouldnt call them barbarians, we shouldnt use the animal characters that were used in their names when they are given names, they are humans.

When the CCP Chinese communist party came to power, they described almost all social issues in the region in terms of what they call an ethnic problem, the minzu wenti. And they thought the way to solve that ethnic problem, ie, how to fit different ethnic groups into Chinas empire, was to classify the groups. So that was called the Ethnic Classification Project, where groups were identified using things like lineage and language records, people were asked which group do you belong to?. And this was in the framework that economic inequality is the root behind ethnic conflict.

So the idea was that developing the region would enable the region to not just economically catch up, but they would become Chinese. So, this shows how their regional policy did have an ethnocentric streak. There was a notion of modernisation thats very similar to colonial motions of modernisation, that essentially cultures develop along a straight line. Deng Xiaoping even said the Han have a special responsibility to modernise Uyghurs.

Gemma: Whats happened between then and now in terms some of the big moments that have defined the way China and the centre have viewed Xinjiang?

David: The big events in sort of the the last 20, 30 years, of course, outbreaks of violence in 2008 before the Beijing Olympics, and the violence in Urumchi in 2009, between Han and Uyghurs.

What was different about them was its people-on-people violence, it wasnt just institutions being attacked. So it was taken as a symbol of deteriorating ethnic relations, and it sparked debates amongst Chinese scholars of how to resolve the ethnic problem in a new era. This was largely a debate between the old school saying focus on economic development, and a new school saying we need rapid assimilation, we need to remove minority languages from education system, and we need to derecognise minorities. Xi Jinpings policy, the language of smelting into rongzhu, that you should have no special rights for minorities, has been celebrated by those scholars as resolving Chinas contradictions. So this is a new direction in policy, but it is based on the underlying idea that Uyghur ethnicity is a security problem that needs to be dealt with.

Gemma: There was violence in 2008 and 2009, and that was followed by more attacks in 2013 and 2014 in Beijing and Kunming which were blamed on Uyghur separatists. How much of what the Chinese state has done in Xinjiang since then is a continuation of that longer history of discrimination and persecution against Uyghurs?

David: This is the real underlying problem, that Uyhgurs are not really seen as human, and then when they start to be seen as human its only because they have to be integrated into China. Its worth noting it didnt have to happen this way. We could have had different turns of events, different leaders with some different ideas.

But when there is a narrative that a people are a security problem, its very difficult to turn that around on the ground when a people know they are targeted as a security problem. And once you have that narrative in official circles, how else can you talk about Uyghurs and Xinjiang without referring to Uyghurs as a security problem?

Gemma: You have spent a lot of time in the region and youve spoken to a lot of Uyghur people as part of your research. When you were there back a decade ago or so, were people using the word genocide at that point or is it only in more recent years that the diaspora that youve talked to have used it? How did they perceive Chinas view of them as, as you say, as barbarians, as terrorist threats and more generally the policies that are happening to wards them in Xinjiang?

David: In Xinjiang, people used assimilation as a norm to explain Chinese policy. It was not necessarily an issue, whether this was genocide, ethnic cleansing, crimes against humanity, its not an international law debate; its just speaking from the heart. So one Uyghur I interviewed in 2011, I asked what he means by assimilation do you mean total assimilation , or do you mean something more subtle? And he says, no, I do mean assimilation. So I ask him would you would tell us what the word is in Chinese tonghua to mean the same. Yep. Hes meaning assimilation. So it is largely a form of genocide in the language being used, and in Uyghur you could even say it as hanzu-leesheesh: to be made Han. So there was no claim that Uyghurs were going to be massacred. But the project of China being in Xinjiang is interpreted as an assimilation project and it is seen as colonialism.

Gemma: Its not just the Uyghurs who see whats going on in Xinjiang as a form of colonialism. In his 2020 book, The War on the Uyghurs, the American anthropologist Sean Roberts argued that the Chinese states actions in the region are a clear example of settler colonialism.

Anna Hayes: Settler colonialism in the form that we saw centuries ago, whereby states would colonise territories and they would overwhelm the indigenous population of that entity so that they could transform that territory into what they wanted it to be.

Gemma: This is Anna Hayes. Shes a senior lecturer at James Cook University in Australia and a fellow of the East Asian Security Centre. I called her up to talk about the economic strategy behind what China is doing in Xinjiang.

Anna: When you think of settler colonialism, you think of places like Australia, New Zealand, Canada, the United States, and the very devastating impact that that had on indigenous populations in those places. And that has an economic driver in it. And thats certainly something that I think were seeing in Xinjiang and when it comes to the economic strategy, how thats playing out is through the belt and road initiative.

Gemma: Broadly, what is Chinas belt and road initiative?

Anna: Its an attempt to connect China to regions and markets far outside of the Chinese mainland, to put in trading routes and economic corridors that will link China through to the Middle East, Central Asia, to Europe. It also has maritime dimensions that sees China hoping to link down into places further field like the South Pacific.

Gemma: Tell us where Xinjiang fits into that plan and why its therefore so important?

Anna: So, for Xinjiang, it sits right in a strategic and pivotal location for the belt and road initiative. It is the gateway to the Middle East, its the gateway to Central Asia, it is also the gateway to Europe.

Gemma: And thats because its literally the most western province, in the top corner of China if youre looking at a map.

Anna: Thats right. And its massive. And it shares a land border with many different states. So it is a massive territory, it takes up almost the entire western part. So within China, theres a real hope that Xinjiang will be massively transformed, itll be a hub of manufacturing, a hub of natural resource extraction I mean, it already is however, that will be expanded.

And cities in Xinjiang, like Kashgar, which is located in southern Xinjiang, and its long been the heart of the Uyghur homeland. Its a beautiful, or was a beautiful, example of traditional Islamic architecture in Central Asia. But since really the late 2000s, the Chinese government in their attempts to develop Kashgar first, and now more radically to completely develop and transform Kashgar into just any other Chinese city. The old city of Kashgar has been smashed down and theres a desire to rapidly increase the population of Kashgar as part of this belt and road push, and to have it as a central gravity of economic focus in the belt and road initiative. And theyve identified nine bases that they want to have Kashgar centred around.

They include textile industry, the large scale metallurgical industrial base, a petrochemical base. They want it as a processing base for agricultural and sideline products, they also want to have export commodity processing and manufacturing base for the neighbouring countries. They also see it as playing a role in Halal food production and supply base for Muslim countries, as well as a buildings materials based for neighbouring countries. A trade logistics base, helping them get that China-Pakistan economic corridor really humming. And they also see it as being an international tourist destination because those little elements of old Kashgar that still remain, theyre wanting to make that a big tourism pull to the region.

Gemma: So all those different elements, is that happening yet or is that still the project in the future?

Anna: Thats still the project in some respects for the future. Other parts of it is already happening. In just the last couple of years, Kashgars population has already grown from 500,000 to 711,000. Theres the plan for it to have a population of over one million.

Gemma: Are these Uyghurs that have been brought from other parts of Xinjiang or are they people from outside the region whove been brought in?

Anna: Theyre a mixture of both. And I think what weve already seen too in Kashgar is that a number of factories that have been identified, they do have dormitories attached to them. Weve seen that with other factories around Xinjiang, that co-location of dormitories to provide the labour to the factories.

Gemma: Where do the Uyghurs fit into this economic strategy for Xinjiang?

Anna: I mean, its difficult to say, because you know, when you think about the connections that the Chinese government is wanting to pursue with economic and business arrangements with the Middle East, the Uyghurs were the ideal trading partners. And for many years prior, they had been. Until Xinjiang was really cut off to other parts of the world by the Chinese government, much of Uyhgur business and trade was with neighbouring states. So, they could have played really quite an instrumental role in connecting China to these other locations. But that is not the way that the government has proceeded.

Instead, I think what they are see is that the Uyghurs will make up the grunt labour force within this economic plan. And this is the other thing with the settler colonial society is that thats typically how indigenous populations are used. Theyre there to do the menial, you know, dirty jobs, alongside increasing numbers of Han Chinese who are migrating to the region because they too are a labour pool that is being used in the belt and road initiative within Xinjiang.

Gemma: Where does this fit into president Xi Jinpings wider project for China, which I know youve written a research paper on recently?

Anna: I guess Xi Jinpings bigger goal here is what he has called the China dream. Its a dream that many leaders have long held, and its really the dream of China returning to a position of great power status, potentially superpower status in the contemporary age. Thats why Xi Jinping talks about it being a great rejuvenation of China and the Chinese nation. And by the Chinese nation, hes meaning the Chinese people and theres racial connotations within there as well.

The belt and road initiative kind of falls underneath that, and Ive called it in my paper interwoven destinies. Its the blueprint for achieving the China dream. So, its the economic strategy that Xi Jinping believes can get China back into that really strong economic position globally.

Gemma: So if you see that the China dream is this bigger top level strategy, the belt and road initiative is a fundamental part of that. And then within the belt and road initiative, whats going on in Xinjiang is a core element. It puts Xinjiang really kind of as a crucial crux point of that China dream.

Anna: Absolutely. And this is one of the critical things about it all; is that for the belt and road initiative to work, Xinjiang has to work. And so thats why weve seen really intensive focus, and repression, and crack down, and the forced labour, the mass detention of one to two million Uyghurs, because Xi Jinping has to make Xinjiang work.

Read more from the original source:
China's plan for Xinjiang, plus what's lurking in your household dust? The Conversation Weekly podcast transcript - The Conversation UK

Bioengineers Have Modeled The Workings of The World’s Most Basic Synthetic Life Form – ScienceAlert

Life is complicated. Even the smallest cells contain a mind-blowing assortment of chemical reactions that allow them to thrive in a chaotic landscape.

If we want to know where to draw the line between life and bubbles of stale old organic soup, it helps to strip away the non-essential extras to expose the core components, and then map how each of them works.

This has been the goal of biochemists for a number of years, who have, over the years, succeeded in designing some surprisingly basic organisms that barely cling to life in a laboratory.

Now, scientists from the J. Craig Venter Institute and the University of Illinois Urbana-Champaign in the US, and the Technische Universitt Dresden in Germany, have taken the next step and constructed a detailed simulation of their latest minimalist microbe.

"What's new here is that we developed a three-dimensional, fully dynamic kinetic model of a living minimal cell that mimics what goes on in the actual cell," says University of Illinois Urbana-Champaign chemist Zaida Luthey-Schulten.

Luthey-Schulten led a team of researchers in analyzing the diverse genetic, metabolic, and structural changes that take place in a replicating culture of synthetic bacteria called JCVI-syn3A.

Simulating the workings of the most basic of organisms, such as species of Mycoplasma or the common microbe Escherichia coli, still requires a few mathematical fudge factors to broadly model the operations of numerous sub-systems. Weaving together the full range of detailed descriptions of everything from the genes up and nutrients down just hasn't been possible, even for these comparatively simple bacteria.

In the early 2000s, researchers at the J. Craig Venter Institute removed as many genes as they could from Mycoplasma mycoides, leaving a version that stood right on the brink of survival.

This synthetic life form, called JCVI-syn1.0, was soon superseded by something even more basic. JCVI-syn3.0.

This updated version contains just 531,000 bases divided among 473 genes. With all of its nutrient needs provided by the laboratory, its bare-bones genome is left to take care of replicating and growing and little else.

Still, JCVI-syn3.0 isn't exactly consistent in its growth, producing a confusing diversity of shapes in its progeny. A few genes were popped back in, resulting in the latest version of the minimal cell: JCVI-syn3A.

Its creators have a solid idea of what genes their synthetic cell contains, though are still working out exactly what each one does.

To make things even more difficult, it's vital knowing how each atom and molecule diffuses through the cell, a description that requires heavy-duty computing power to simulate.

"We developed a three-dimensional, fully dynamic kinetic model of a living minimal cell," says Luthey-Schulten.

"Our model opens a window on the inner workings of the cell, showing us how all of the components interact and change in response to internal and external cues. This model and other, more sophisticated models to come will help us better understand the fundamental principles of life."

The simulation confirmed a few suspicions, however, such as the fact most of the minimalist cell's energy went towards dragging in essential materials across the membranes.

It also gave an accurate description of the timelines of genetic and metabolic reactions, explaining relationships between the rate of production of lipids and proteins in the membrane and changes in the cell's shape.

Since JCVI-syn3A are essentially pared-down versions of a naturally occurring organism, they're just one example of how to minimalize the functions of biology. Life is nothing if not creative in how it overcomes obstacles to survival.

Now that we have a proven model for simulating JCVI-syn3A's growth and development, researchers can build up its complexity again to determine how different genes add to its function.

We might expect new 'lite' versions of not just M. mycoides, but other organisms in the near future. If not completely novel synthetic life forms.

Life might still be complicated, but it just got a whole lot easier to study.

This research was published in Cell.

Read the original post:
Bioengineers Have Modeled The Workings of The World's Most Basic Synthetic Life Form - ScienceAlert

Caltech Faculty Members and JPL Researcher Named as AAAS Fellows – Caltech

Four Caltech professors, along with one principal staff member from the Jet Propulsion Laboratory, have been named as fellows of the American Association for the Advancement of Science (AAAS). In total, 14 Caltech alumni were named as fellows this year.

AAAS Fellows are a distinguished cadre of scientists, engineers, and innovators who have been recognized for their achievements across disciplines, from research, teaching, and technology, to administration in academia, industry, and government, to excellence in communicating and interpreting science to the public. The 2022 class of AAAS Fellows includes 564 scientists, engineers, and innovators spanning 24 scientific disciplines.

William G. Dunphy

Grace C. Steele Professor of Biology

"For elucidating the complex network of enzymes that commit a cell to mitosiscritical information for understanding DNA replication and preservation of genomic integrity."

Dunphy received his PhD from Stanford in 1985. He joined the Caltech faculty in 1989.

Viviana Gradinaru (BS '05)

Professor of neuroscience and biological engineering; director, Center for Molecular and Cellular Neuroscience

"For extraordinary achievements in bioengineering and neuroscience, including development and sharing of multiple novel tools to enable functional and anatomical access to the vertebrate nervous system."

Gradinaru received her PhD from Stanford in 2010. She joined the Caltech faculty in 2012.

Stephen Mayo (PhD '87)

Bren Professor of Biology and Chemistry; Merkin Institute Professor

"For distinguished contributions to the field of protein design technology."

Mayo received his PhD from Caltech in 1987. He joined the faculty in 1992.

Carol Polanskey (MS '84, PhD '89)

Planetary scientist, JPL

"For distinguished contributions to the field of planetary science, especially the structure and dynamics of asteroids and other small planetary bodies as well as exemplary leadership and development of space science missions."

Polanskey received her PhD from Caltech in 1989.

Paul O. Wennberg

R. Stanton Avery Professor of Atmospheric Chemistry and Environmental Science and Engineering; executive officer for environmental science and engineering; director, Ronald and Maxine Linde Center for Global Environmental Science

"For major scientific advances in atmospheric chemistry."

Wennberg received his PhD from Harvard in 1994. He joined the Caltech faculty in 1998.

In addition to Gradinaru, Mayo, and Polanskey, 11 other Caltech alumni were elected as AAAS fellows this year: Andrea M. Armani (MS '03, PhD '07), Pratim Biswas (PhD '85), Eric Christian (MS '85, PhD '89), Brian C. Freeman (BS '79), Stephen Craig Hadler (BS, '69), Thomas Mark McCleskey (PhD '94), Charles Ofria (PhD '99), Padhraic Smyth (MS '85, PhD '88), Lynmarie K. Thompson (BS '83), Paula I. Watnick (PhD '89), and Yannis Yortsos (MS '74, PhD '79).

See more here:
Caltech Faculty Members and JPL Researcher Named as AAAS Fellows - Caltech

Global ?-Polylysine Market 2021 COVID-19 Impact Analysis and Top Companies as Jnc-Corp, Siveele, Handary, Zhejiang Silver Elephant Bioengineering The…

Global ?-Polylysine Market from 2021 to 2027 is the professional market research study by MRInsights.biz covering growth prospects and market development potential. The report offers the overall industry structure, explaining the market summary, specification, product definition, and objectives.It also has separate chapters that include the regional studies to get a picture of the markets with future opportunities followed by the estimated yearly growth during the survey period from 2021 to 2027.

The document presents the business customers with an in-depth review of the global ?-Polylysine market, giving an evaluation of the market trends, market size, market value, and market growth over the forecast duration on a compound in addition to on a yearly basis. The study clarifies the market situation and forecast subtleties of the essential zones, with the logical presentation of preeminent producers, product types, and end-client associations.

DOWNLOAD FREE SAMPLE REPORT: https://www.mrinsights.biz/report-detail/241151/request-sample

A global attitude on substantial regions is also protected in the document, particularly

Product offers, revenue analysis, manufacturing capabilities, gross margins, and several different critical factors that affect a companys profitability in the market also are included. Market segment by type, the product is divided into

The document enumerates information approximately business phase of the market:

The evaluation of the following companies has been provided in the report:

ACCESS FULL REPORT: https://www.mrinsights.biz/report/global-polylysine-market-growth-2021-2026-241151.html

An extensive evaluation based on the market segment might be beneficial to enhance the commercial enterprise development. This report also gives SWOT evaluation, funding feasibility evaluation, and funding go again evaluation.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@mrinsights.bizWeb: http://www.mrinsights.biz

See more here:
Global ?-Polylysine Market 2021 COVID-19 Impact Analysis and Top Companies as Jnc-Corp, Siveele, Handary, Zhejiang Silver Elephant Bioengineering The...

Research Fellow, Biomedical Engineering job with NATIONAL UNIVERSITY OF SINGAPORE | 279034 – Times Higher Education (THE)

Job Description

We are seeking a highly motivated Research Fellow with expertise in bioengineering, biomaterials and cellular engineering.

The candidate will be responsible for fabricating materials including nanoparticles and nano-needles for use in genetic engineering of cells. The candidate will also need to independently design and execute experiments, troubleshoot issues, interpret results and give project updates.

We provide a highly competitive remuneration package that commensurates with the qualifications and relevant experience of the successful candidate. The candidate will also be fully supported in their career development in different areas like research, industry, consulting and education.

Qualifications

To apply, please send your CV and contact details of two referees to Dr Andy Tay (bietkpa@nus.edu.sg) Only shortlisted candidates will be contacted.

More Information

Location: Kent Ridge CampusOrganization: EngineeringDepartment : Biomedical EngineeringEmployee Referral Eligible: NoJob requisition ID : 8619

See more here:
Research Fellow, Biomedical Engineering job with NATIONAL UNIVERSITY OF SINGAPORE | 279034 - Times Higher Education (THE)

NIH Funds Protease Research Advancing Understanding of Cancer Progression and Treatments – Lehigh University News

While other systems that enable the visualization of protease activity exist, Pashucks method was designed to have lower background fluorescence (increasing imaging quality) and enable visualization of multiple proteases at the same time.

Pashuck aims to develop protease-responsive conjugates, incorporate them into hydrogels and visualize spatiotemporal protease activity in model tissue, including hydrogels containing both cancerous and noncancerous cells to better understand metastatic processes.

This approach is powerful because it can be easily adapted by other labs, can be used for many proteases and incorporated into most biomaterial systems, Pashuck said in the project summary. Since proteases catalyze the cleavage of a peptide bond, they are especially useful for making stimuli-responsive therapies. Thus this research can help researchers across disciplines develop more effective biomedical interventions.

Cancer is the second leading cause of death in the United States and about 40% of people will be diagnosed with cancer at some time in their lives. Understanding the complex interactions that occur within the tumor microenvironment is crucial for creating more effective therapies to inhibit the processes that lead to poor treatment options, Pashuck said.

Drugs targeting protease activity have entered clinical trials, but so far have not been successful. New protease therapies that have improved enzyme specificity have been developed. Increasing our understanding of protease activity in the tumor microenvironment is needed to bring such promising drugs to the clinic, Pashuck said.

Pashuck, the principal investigator, is working on the project with Lehigh University graduate student Sam Rozans. The total funding amount is $408,493.

Link:
NIH Funds Protease Research Advancing Understanding of Cancer Progression and Treatments - Lehigh University News

Intranasal Flu Vaccine with Nanoparticles to Enhance Immunity Offers Robust Protection, Biomedical Sciences Researchers Find – Georgia State…

ATLANTAAn influenza vaccine administered through the nose and constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

The intranasal vaccine contributed to multifaceted immune responses, leading to robust cross protection against influenza in mice. The vaccine consists of PEI-HA/CpG nanoparticles. PEI (polyethyleneimine), a robust and versatile delivery system, can simultaneously carry antigens (hemagglutinin, HA) that induce an immune response in the body, and adjuvants (CpG) that enhance the bodys immune response to an antigen for optimal immunoenhancement.

These comprehensive immune responses and cross protection were long lasting, exhibiting defense from influenza virus over six months after immunization. The findings are published in the journal ACS Applied Materials & Interfaces.

Intranasal vaccination is an ideal approach for infectious respiratory diseases such as influenza. Seasonal influenza vaccines generally induce narrow immune responses that rapidly decline, which leaves populations vulnerable to novel influenza strains. Advancements in influenza vaccine technology are needed to protect against a wide range of influenza viruses. Intranasal vaccination can improve local mucosal immune responses by preventing influenza infection at the portal of virus entry.

In the influenza virus, HA is a protein that plays a crucial role in the early stages of virus infection. Influenza HA has a head region and stalk region. Current influenza vaccines elicit immune responses against the HA head, but this head region is highly changeable and accounts for lowered efficiency against different strains. The HA stalk region is more conservative across different strains of influenza viruses.

Protein antigens that are administered intranasally are usually less able to provoke an immune response, so adjuvants are needed to have highly efficient intranasal vaccines. Adjuvants, such as CpG, can enhance and manipulate immune responses, thus improving the potency and breadth of protection.

The PEI-HA/CpG nanoparticles show good potential as a cross-protective influenza vaccine candidate, said Dr. Baozhong Wang, corresponding author of the study and a professor in the Institute for Biomedical Sciences at Georgia State. The combination of PEI and CpG in the PEI-HA/CpG nanoparticle group contributed to the multifaceted immune responses, leading to vigorous cross protection. The incorporation of CpG and antigens into the same nanoparticle enhanced cellular immune responses.

Our results revealed that the nanoparticles significantly enhanced HA immunogenicity, or the ability to provoke an immune response, providing cross protection against different influenza virus strains. The conserved HA stalk region induced substantial antibodies in the nanoparticle immunization groups.

Nanoparticle platforms have shown intriguing characteristics and great potentials in thedevelopment of next-generation cross-protective influenza vaccines, said Dr. Chunhong Dong, the first author of the study and a postdoctoral fellow in theInstitute for Biomedical Sciences. However, challenges exist to the successful research and development of nanoparticle vaccines. Though no apparent adverse effects were observed in the study, a more comprehensive safety evaluation of the nanoparticle adjuvant system is needed before clinical trials.

Co-authors of the study include Baozhong Wang, Chunhong Dong (first author), Ye Wang, Wandi Zhu, Yao Ma, Joo Kim, Lai Wei and Gilbert X. Gonzalez.

The study was funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

To read the study, visit https://pubs.acs.org/doi/10.1021/acsami.1c19192.

Read more from the original source:
Intranasal Flu Vaccine with Nanoparticles to Enhance Immunity Offers Robust Protection, Biomedical Sciences Researchers Find - Georgia State...

Faculty at Brown earn prestigious awards, distinctions – Brown University

PROVIDENCE, R.I. [Brown University] The COVID-19 pandemic has disrupted activities across the globe but it hasnt stopped Brown faculty from making a positive impact through research and scholarship.

Over the last year, faculty members at Brown have been honored for outstanding research, service and leadership in their fields of study with numerous awards, fellowships and other honors. The scholars, whose fields range from literary arts and education to applied math and biostatistics, earned both national and international recognition and support for their work.

Among such distinctions were the following honors:

Dr. Jasjit Singh Ahluwalia, a professor of medicine and behavioral and social sciences, was invited to serve on the Food and Drug Law Institutes 2020 Tobacco and Nicotine Products Committee, which brings diverse stakeholders together for high-level discussions on tobacco products regulation and policy.

Ahmed Abdelfattah, an assistant professor of neuroscience, was one of 15 scientists named as Searle Scholars for 2021, an honor that came with $300,000 over three years to support his research. Abdelfattah, who is affiliated with Browns Carney Institute for Brain Science, uses bioengineering and chemical approaches to develop molecular tools to visualize and study the brain.

Ariella Azoulay, a professor of modern culture and media and comparative literature, was among 22 scholars, writers, artists and composers to receive the prestigious Berlin Prize in the 2021-22 academic year. Azoulay will spend a semester at the American Academy in Berlins lakeside Hans Arnhold Center, a historic 19-century villa, writing a series of letters as part of a larger effort to draw attention to the experiences of Algerian Jews.

Yuri Bazilevs, a professor of engineering, won the 2021 American Society of Mechanical Engineers Materials Division Centennial Mid-Career Award, which recognizes impactful work at the interface of materials and mechanics. Bazilevs work in computational mechanics addresses problems ranging from renewable energy to blood flow in the heart.

Sara Becker, an associate professor of behavioral and social sciences and psychiatry and human behavior, won the 2020 G. Alan Marlatt Mid-Career Research Award from the Association for Behavioral and Cognitive Therapies for her program of rigorous research in the field of addiction psychology.

Dr. Justin Berk, an assistant professor in the departments of medicine and pediatrics at the Warren Alpert Medical School, was among eight early-career physicians and researchers to be selected by the American Board of Medical Specialties to participate in its 202021 Visiting Scholars Program. During the yearlong, part-time scholarship and leadership development program, Berks research will focus on the role of medical education podcasts in continuing professional development.

Dr. Richard W. Besdine, a professor of medicine and health services, policy and practice, received the Charles Bud Kahn, M.D., Lifetime Leadership Award from the Miriam Hospital Medical Staff Association for "outstanding leadership over a lifetime of service." Besdineretired from his position as director of the division of geriatrics and palliative medicine in the department of medicine, and chief of geriatrics, for Lifespan after 20 years of service.

Melody Chan, an associate professor of mathematics, was named a 2022 fellow of the American Mathematical Society, a designation that recognizes people who have made outstanding contributions to the creation, exposition, advancement, communication and utilization of mathematics. Chan was honored for her research at the interface of algebraic geometry and combinatorics, and for mentorship and mathematical exposition.

Associate Professor of Behavioral and Social Sciences Patricia Cioe was named by the University of Rhode Island College of Nursing as one of 75 luminaries representing the best nurses and nurse scientists to have come through its nursing program over the years, excelling in professional practice, education, research and advancement of the college, and making lasting contributions to the profession of nursing.

Professor of Modern Culture and Media Anthony Cokes has been selected to participate in the 2022 Whitney Biennial, which features a constellation of some of the most relevant art and ideas produced by Americans in the last two years. Work by Cokes will be on display at New Yorks Whitney Museum of American Art from April to September 2022.

Pradeep Guduru, a professor of engineering, won the 2020 James R. Rice medal from the Society of Engineering Science. Named for a former Brown professor, the award celebrates pioneering contributions to the field of engineering sciences. Guduru was honored for his work in energy storage, catalysis, surface adhesion and other areas.

David Henann, an associate professor of engineering, received the 2020 Eshelby Mechanics Award for Young Faculty from the American Society of Mechanical Engineers. Henann, who studies the physics of granular materials, was honored for creative use and development of mechanics in his research.

Tim Herbert, a professor of Earth, environmental and planetary sciences, was named a 2020 fellow of the American Geophysical Union, an honor bestowed on 0.1% of the AGUs 60,000 members. Herbert reconstructs ocean temperature and biological production through time.

Professor of Literary Arts Laird Hunt was a finalist for a National Book Award in the fiction category for his novel Zorrie. Hunts novel follows a woman searching for her place in the world and finding it in the daily rhythms of life in rural Indiana. Since 1950, the National Book Award has celebrated much of the best writing in the United States.

Sorin Istrail, a professor of computer science, was one of 13 top researchers elected as 2021 Fellows of the International Society for Computational Biology. Before coming to Brown, Istrail was head of informatics research at Celera Genomics, where his group played a central role in the construction of the sequence of the human genome. At Brown, he develops computational methods for cutting edge genomic research.

Dr. Ashish K. Jha, dean of the School of Public Health, was honored with the Meeting the Moment in Public Health Award from Johnson & Johnson Research! America. Jha was recognized for playing a key role in communicating public health information and developments to members of the public and for his masterful ability and tireless commitment to conveying key information about COVID-19 to a wide array of audiences.

George Karniadakis, a professor of applied math and engineering, received the SIAM/ACM Prize in Computational Science and Engineering in March 2021 for pushing applications to extreme computational scales and mentoring many leaders in the field of computational modeling. The award is given biennially by the Society for Industrial and Applied Mathematics and the Association for Computing Machinery.

Associate Professor of Education Matthew Kraft was given the Society for Research on Educational Effectiveness Early Career Award for his research on efforts to improve teacher and organizational effectiveness in K-12 public schools. Matt has become a leading national voice on education policy, read a statement from a colleague who nominated Kraft for the award. His research and public engagement has helped shape the national dialogue on how best to design and implement effective teacher evaluation systems.

Greg Landsberg, a professor of physics, was named chair of the publications committee for the CMS Collaboration, one of the major particle physics experiments happening at the Large Hadron Collider in Geneva, Switzerland. The publications committee assures the quality of around 100 research papers produced by the CMS Collaboration each year.

Dr. Tracy Madsen, an associate professor of epidemiology and emergency medicine, was selected by the National Academy of Medicine as the 2021 American Board of Emergency Medicine Fellow. During her two-year fellowship, Madsen will collaborate with eminent researchers, policy experts and clinicians from across the country and will help facilitate initiatives convened by the National Academies to provide nonpartisan and evidence-based guidance to policymakers, academic leaders, health care administrators and the public.

Francesca Mari, a visiting lecturer in literary arts, was awarded a fellowship by the organization New America, which gives new generations of policy experts and public intellectuals the time, space and resources to confront societys most pressing problems through research, reporting and analysis. As a New America Fellow, Mari is writing a book about why housing in the U.S. is so expensive, charting the consequences of financialization on the lives of neighbors on a single block in Los Angeles.

Associate Professor of Brain Science Kate O'Connor-Giles was one of five recipients of the 2021 National Institute of Neurological Disorders and Stroke Landis Award for Outstanding Mentorship by an NINDS Investigator. The award recognizes faculty members who have shown dedication to superior mentorship and training in neuroscience research, and includes a $100,000 grant supplement to support efforts to foster the career advancement of additional trainees.

Iris Montero Sobrevilla, an assistant professor of Hispanic studies, won the 2021 Robert F. Heizer Article Award for The Disguise of the Hummingbird: On the Natural History of Huitzilopochtli in the Florentine Codex. The award, granted by the American Society for Ethnohistory, recognizes the best article in the field of ethnohistory and seeks to feature cross-disciplinary approaches to Indigenous histories.

Dr. Christine Montross, an associate professor of psychiatry and human behavior, and medical science, was a finalist for a 2020 L.A. Times Book Prize in the current interest category for her nonfiction book, Waiting for an Echo: The Madness of American Incarceration. In what the L.A. Times called a riveting glimpse into Americas prison system, Montross, a practicing inpatient psychiatrist, illuminates the human cost of mass incarceration and mental illness.

Elias Muhanna, an associate professor of comparative literature and history, was awarded the 2022 John Nicholas Brown Prize for his monograph The World in a Book: Al-Nuwayri and the Islamic Encyclopedic Tradition. Awarded by the Medieval Academy of America, the prize is awarded annually for a first book or monograph on a medieval subject judged by the selection committee to be of outstanding quality.

Assistant Professor of Literary Arts Sawako Nakayasu received a $35,000 fellowship for digital publication from the National Endowment for the Humanities and the Andrew W. Mellon Foundation. The fellowship will enable Nakayasu to conduct research for a digital monograph on the reception and legacy of modernist Japanese poet Chika Sagawa.

Jayanti Owens, an assistant professor of international and public affairs and sociology, was selected as a 2020 William T. Grant scholar. With a $350,000 award, Owens will develop different aspects of an ongoing project investigating what drives racial and ethnic disparities in school discipline. Launched in 1982, the prestigious William T. Grant scholars program supports the professional development of early career researchers in the social, behavioral and health sciences.

Owens also received the Promising Scholar Award from the Foundation for Child Development for her research on school discipline disparities. The foundation seeks to help researchers, policymakers and advocates develop high-quality, evidence-based early childhood systems to serve the needs of all children.

Applied mathematics professor Kavita Ramanan was named a 2021 Vannevar-Bush Faculty Fellow, the most prestigious research award from the U.S. Department of Defense. The $3 million award supports supports out-of-the-box ideas where researcher creativity intersects with the unknown. Ramanans research in probability theory and stochastic processes investigates the uncertain outcomes and random effects that pervade science, engineering and everyday life.

Dr. Ranna Rozenfeld, a professor of pediatrics who specializes in pediatric critical care medicine, is one of 55 new members of the American Pediatric Society. New members are nominated by current members through a process that recognizes individuals who have distinguished themselves as child health leaders, teachers, scholars, policymakers and/or clinicians.

Brenda Rubenstein, a professor of chemistry, won a 2021 Teacher-Scholar Award from the Camille and Henry Dreyfus Foundation. She was one of 16 people nationwide to win the award, which goes to faculty within the first five years of their academic careers who have created an outstanding body of scholarship and are deeply committed to education. Rubenstein was also named one of Popular Sciences Brilliant 10, the magazines list of the most innovative up-and-coming minds in science.

Jim Russell, a professor and chair of Earth, environmental and planetary sciences, won the Willi Dansgaard Medal from the American Geophysical Union, which honors high-impact, interdisciplinary work in paleoceanography and paleoclimatology. Russell uses key indicators trapped in lake and ocean sediments to reconstruct past climate conditions.

Dr. Samir A. Shah, a clinical professor of medicine at Brown and chief of gastroenterology at the Miriam Hospital, was elected the 2021-22 president of the American College of Gastroenterology, a national medical organization representing more than 17,000 clinical gastroenterologists and other specialists in digestive diseases. Shah will direct ACGs programs, which include continuing medical education in the clinical, scientific and patient-related skills of gastroenterology; activities involving national and state medical affairs; health policy issues; and clinical investigation.

Chi-Wang Shu, a professor of applied mathematics, was awarded the 2021 John von Neumann Prize by the Society for Industrial and Applied Mathematics. The prize is awarded for outstanding and distinguished contributions to the field of applied mathematical sciences and for the effective communication of these ideas to the community.

Anita Shukla, an associate professor of engineering, won a Dr. Ralph and Marian Falk Medical Research Trust Transformational Award. The $1 million award is intended to provide the bridge to the technology transfer process for moving an exciting health care innovation to the next step in commercial development. Shukla is investigating the antibacterial potential of hydrogels, with the expectation that these materials will greatly improve treatment options for difficult to treat wounds prone to infection, such as diabetic ulcers and burns.

Chemistry professor Richard Stratt won the 2021 Joel Henry Hildebrand Award in the Theoretical and Experimental Chemistry of Liquids from the American Chemical Society. Stratts research group studies molecular mechanisms of events such as solvation and vibrational relaxation the elementary steps that determine the course of chemical reactions in liquids.

Adam Teller, a professor of history and Judaic studies, was named a National Jewish Book Awards finalist in the history category for his book Rescue the Surviving Souls: The Great Jewish Refugee Crisis of the Seventeenth Century. The National Jewish Book Awards were established by Jewish Book Council in 1950 to recognize outstanding works of Jewish literature.

Associate Professor of Health Services, Policy and Practice Kali Thomas was the inaugural recipient of the Terrie Fox Wetle Rising Star Award in Health Services and Aging Research from the American Federation for Aging Research for her work applying health services research to inform policies and practices that improve health and quality of life for older adults. The award is name for the founding dean of Browns School of Public Health.

Kimani Toussaint, a professor and associate dean of engineering, was elected to the American Institute for Medical and Biological Engineering College of Fellows, a select group of the top two percent of medical and biological engineering professionals. Toussaint was elected for his outstanding contributions to biomedical engineering using both novel photonic materials and optical imaging systems.

Assistant Professor of Humanities Daniel Vaca received an honorable mention in the Modern Language Associations Matei Calinescu Prize announcement for his book Evangelicals Incorporated. The prize committee shared that Vacas book uncovers a new archive for the history of religion in the United States: the flourishing for-profit business of evangelical publishing.

Lai-Sheng Wang, professor and chair of chemistry, won the 2020 E. Bright Wilson Award in Spectroscopy from the American Chemical Society. Wangs lab creates new forms of matter called nanoclusters, then uses a technique called photoelectron spectroscopy to study their properties one atom at a time. His discoveries include boron analogs to the carbon nanomaterials graphene and fullerene.

Ian Wong, an associate professor of engineering, was one of 60 of the most promising early career engineers from the United States and Japan chosen to participate in the National Academy of Engineerings 2021 Japan-America Frontiers of Engineering Symposium. Wong engineers new miniaturized technologies based on biomaterials and microfluidics to investigate cancer cell invasion, drug resistance and heterogeneity.

Kenneth Wong, a professor of international and public affairs, education policy and political science, was among 39 leaders who were elected as new fellows of the National Academy of Public Administration in 2021. As a NAPA fellow, Wong joins a cadre of former cabinet officers, members of Congress, governors, mayors and state legislators, prominent scholars, business executives, nonprofit leaders and prominent public administrators.

Samuel Zipp, an associate professor of American studies and urban studies, was awarded the Robert H. Ferrell Prize for his book The Idealist: Wendell Willkies Longtime Quest to Build One World. The prize, given annually by the Society for Historians of American Foreign Relations, is designed to reward distinguished scholarship in the history of American foreign relations, broadly defined. Members of the prize committee heralded Zipps book as enormously inventive richly researched and written with verve and artfulness.

Andrew R. Zullo, an assistant professor of health services, policy and practice and epidemiology, was named a 2020 Health in Aging Foundation New Investigator Awardee by the American Geriatrics Society for his original research reflecting new insights in geriatrics and his commitment to the disciplines role in academia.

In early January 2022, six faculty members from Brown were among 200 American scholars recognized by Education Week for their highly influential educational research. The annual Edu-Scholar Public Influence Rankings seek to spotlight United States researchers who did the most to shape educational practice and policy in the last year. Among those listed were Professor of Economics Emily Oster; Director of the Annenberg Institute for School Reform Susanna Loeb; Associate Professor of Education Matthew Kraft; Professor of Sociology Prudence Carter; Associate Professor of Education Policy Lindsay Page; and Associate Professor of Education John Papay.

Originally posted here:
Faculty at Brown earn prestigious awards, distinctions - Brown University

Global Bovine-based Collagen for Biomedical Applications Market likely to touch new heights by end of forecast period 2021-2027 Share and Future…

MarketsandResearch.biz has just released Global Bovine-based Collagen for Biomedical Applications Market from 2021 to 2027, a global study report that combines industry expertise, unique ideas, practical solutions, and cutting-edge technology to improve the user experience. The research is a great way to learn about the global Bovine-based Collagen for Biomedical Applications market, emerging trends, product applications, customer and competitor motivators, brand positioning, and consumer behaviour.

The research is based on precise findings from a range of high-end business models, including Porters five forces analysis and SWOT analysis. The study is founded on a thorough examination of a variety of elements, including difficulties, market dynamics, competitive evaluations, market size, issues, and the organisations involved.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/210273

By product types of Bovine-based Collagen for Biomedical Applications market:

The global Bovine-based Collagen for Biomedical Applications market study is separated into applications, such as

The research contains a detailed examination of each parameter, allowing our users to identify the most likely and perhaps best trend in the current environment. The following nations were identified as the most significant in the market research:

Participants in the global market who are well-known and growing:

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/210273/global-bovine-based-collagen-for-biomedical-applications-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026

Frequently Asked Questions

What are the major reasons driving market expansion in Bovine-based Collagen for Biomedical Applications?

Which region will contribute the most revenue to the worldwide Bovine-based Collagen for Biomedical Applications Market?

What are the key players doing to capitalise on the expansion of the Bovine-based Collagen for Biomedical Applications Market?

How much will the Bovine-based Collagen for Biomedical Applications Market be worth between 2021 and 2027?

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.biz

Continue reading here:
Global Bovine-based Collagen for Biomedical Applications Market likely to touch new heights by end of forecast period 2021-2027 Share and Future...

New therapy to tackle obesity by NTU team uses gel and infrared light, safety shown in trials on mice – The Straits Times

SINGAPORE - Scientists from Nanyang Technological University (NTU) have developed a therapy that uses a gel and infrared light to burn fat - a possible safer treatment for people working to control their weight.

Drugs that tackle obesity are meant to accompany exercise and a healthy diet in helping people who are severely obese, including those who have metabolic disorders, but many in the market come with side effects.

Laboratory trials by the NTU team from the School of Chemical and Biomedical Engineering show that mice on a high-fat diet that underwent its therapy weighed 5.5 per cent lighter after two weeks, and lost between 40 per cent and 50 per cent of body fat.

In the therapy, a transparent gel - called a hydrogel - developed by the scientists, is injected into a layer of fat under the mice's skin.

Aninfrared light is then shone on the injection site for five minutes a few times a day to trigger the hydrogel's fat-burning ability.

Infrared light refers to wavelengths of light that are not visible to the human eye, but can be felt as heat.

When exposed to the infrared light, nanoparticles in the hydrogel convert light into heat to activate a protein in the body that kick-starts the fat-burning process.

In this process, white fat - which stores excess calories and leads to weight gain - is converted into calorie-burning tissue.

"Fat cells become energy-burning instead of energy-storing," said bioengineering professor Chen Peng, who led the study.

After two weeks of the treatment - which includes eight days of rest - the mice lost 40 per cent of the fat under their skin and 54 per cent of the fat surrounding their internal organs.

The rodents also had lower cholesterol levels and reduced resistance to insulin, suggesting that the procedure has the potential to reduce the risk of metabolic disorders, said NTU in a statement on Tuesday (Jan 25).

Touching on the therapy's safety, the research team said the hydrogel nanoparticles - made of copper sulphide - have negligible toxic effects on vital organs and tissues.

And although the process uses heat converted from the infrared light to burn fat under the skin, the team found no thermal injury to the mice's skin, said Prof Chen.

The hydrogel also contains substances that are approved by the United States Food and Drug Administration (FDA). For instance, the gel contains an FDA-approved drug for people with overactive bladders, which the NTU team repurposed for its therapy.

The team envisions the therapy being used as a home treatment one day.

Read the original here:
New therapy to tackle obesity by NTU team uses gel and infrared light, safety shown in trials on mice - The Straits Times

Histidine Market Growth, Future Prospects And Competitive Analysis 2021 to 2027 Kyowa Hakko Bio, Ajinomoto, Shine Star Biological Engineering,…

The study incorporates financial analysis, segmentation of comments, market structure analysis, and regional analysis of the different segments of Global Histidine Market from 2021 to 2027 research report recently released by MarketsandResearch.biz. Historical facts and trustworthy information sources are used in the research. The report forecasts a marked increase in the present and future.

The study comprises graphs, statistical, numerical, and graphical formats that provide the end customer a clear view of market attractiveness. The report also offers essential product information and information on Histidine suppliers and distributors.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/163791

The principal enterprises are represented on the global market:

Geographical scrutiny of the following regions and the following national/local markets:

These kinds are classified in this report:

The study underlines various market categories of applications:

The research offers a thorough assessment of Histidine worldwide business customers markets, including trends, market size, market value, and market growth for composite and annualized products during the forecast period. This research analyses the companys prospects thoroughly.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/163791/global-histidine-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026

OBJECTIVE OF THE RESEARCH REPORT:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.biz

Continued here:
Histidine Market Growth, Future Prospects And Competitive Analysis 2021 to 2027 Kyowa Hakko Bio, Ajinomoto, Shine Star Biological Engineering,...

Global Cosmetic Grade Lanolin Alcohol Market to Experience Significant Growth during the Forecast Period 2021-2027 The Oxford Spokesman – The Oxford…

The research report demonstrates vital and necessary market information on the Global Cosmetic Grade Lanolin Alcohol Market from 2021 to 2027. The most recent research from MarketsandResearch.biz includes information on the industrys current environment in various areas and actual data and market projections. The study also provides sales and demand statistics for the Cosmetic Grade Lanolin Alcohol market in multiple sectors and geographies. The report examines future potential and market circumstances for 2021-2027, rendering insights and updates on the global markets connected segments Cosmetic Grade Lanolin Alcohol.

The examination includes new rivals identified in the global market study of Cosmetic Grade Lanolin Alcohol. Business pictures, geographical presence, product portfolio, and current advances are all taken into account while analysing company profiles. It displays critical metrics and manufacturer asserts and may be a valuable source of assistance for businesses and organizations.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/195962

It provides a comprehensive analysis of Cosmetic Grade Lanolin Alcohol market segments according to type:

Bleached Lanolin Alcohol, Conventional Lanolin Alcohol

It provides detailed research of the Cosmetic Grade Lanolin Alcohol market segments based on application:

Topical Skin Preparation, Cosmetics, Other

The study includes the following key market industry vendors:

Dishman, Weleda, Deutsche Lanolin Gesellschaft, Zhejiang Garden Biochemical, NK Ingredients, Nippon Fine Chemical, Heyang Suntech Bioengineering

The report emphasizes the regional sector analysis:

North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia), South America (Brazil, Argentina, Colombia, and Rest of South America), Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/195962/global-cosmetic-grade-lanolin-alcohol-market-2021-by-manufacturers-regions-type-and-application-forecast-to-2026

The following market parameters were investigated in the study:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.biz

Read the original here:
Global Cosmetic Grade Lanolin Alcohol Market to Experience Significant Growth during the Forecast Period 2021-2027 The Oxford Spokesman - The Oxford...

Outlook on the Microarray Global Market to 2027 – by Type, Application and Region – PRNewswire

DUBLIN, Jan. 26, 2022 /PRNewswire/ -- The "Microarray Market 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The global microarray market is anticipated to grow at a substantial CAGR of 7.8% during the forecast period. The global microarray market is driven by the rising prevalence of cancer as well as increased funding for genomic research.

Additionally, the rapidly evolving information and software technology, as well as emerging bioinformatics, are also some of the factors driving the microarray market, making it cost-effective, dependable, and long-lasting. However, a lack of skilled professionals and the growing penetration of next-generation DNA sequencing techniques are considered to address significant challenges to market growth.

The global microarray market witnessed positive growth during the COVID-19 pandemic as huge efforts to manufacture vaccines, develop new drugs, deployment of test kits was fueling the growth of the biotechnology sector. The COVID-19 pandemic has also increased the use of microarrays techniques in pharmaceutical research.

The global microarray market is segmented based on type, and application; Based on type, the market is segmented into DNA microarrays, protein microarray, peptide microarray, tissue microarray, and others (cellular microarray). Further based on application, the market is segregated into diagnosis and prognosis, Pharmacogenomics and theragnostic, and drug discovery, and others. The DNA Microarray segment is expected to have a significant share of the global microarray market attributing to the increasing applications of the DNA microarray approach in various sectors, such as gene expression, proteomics, disease monitoring, and drug discovery.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is the fastest-growing market for microarray. Factors such as increased emphasis on personalized medicine, an increase in cancer diagnostic rates, and technological advancements are largely responsible for fueling the growth of this market. The Asia-Pacific region is also expected to grow significantly as a result of increased government funding in the healthcare sector. As per IBEF, the healthcare sector in India received $679 million in investment in 2018. These government initiatives are expected to increase demand for microarrays used in research, therefore, fueling the demand for microarrays in the Asia-Pacific market.

Market Segmentation

The Report Covers

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights2.1. Scope of the Report2.2. Analyst Insight & Current Market Trends2.2.1. Key Findings2.2.2. Recommendations2.2.3. Conclusion2.3. Regulations

3. Competitive Landscape3.1. Key Company Analysis3.1.1. Overview3.1.2. Financial Analysis3.1.3. SWOT Analysis3.2. Key Strategy Analysis3.3. Impact of COVID-19 on key players

4. Market Determinants4.1. Motivators4.2. Restraints4.3. Opportunities

5. Market Segmentation5.1. Global Microarray Market by Type5.1.1. DNA Microarrays5.1.2. Protein Microarray5.1.3. Peptide Microarray5.1.4. Tissue Microarray5.1.5. Others (Cellular Microarray)5.2. Global Microarray Market by Application5.2.1. Diagnosis and Prognosis5.2.2. Pharmacogenomics and Theragnostic5.2.3. Drug Discovery5.2.4. Others

6. Regional Analysis

7. Company Profiles7.1. Abcam PLC7.2. Agilent Technologies, Inc.7.3. Applied Microarrays, Inc.7.4. Arrayit Corp.7.5. Aurora Biomed Inc.7.6. Bio-Rad Laboratories, Inc.7.7. F. Hoffmann-La Roche Ltd.7.8. Merck KGaA7.9. Meso Scale Diagnostics, LLC.7.10. Origene Technologies, Inc.7.11. Pantomics, Inc.7.12. Partek, Inc.7.13. PerkinElmer, Inc.7.14. Takara Bio, Inc.7.15. Thermo Fisher Scientific, Inc.7.16. US Biomax, Inc.7.17. Illumina, Inc.7.18. Indevr, Inc.7.19. Luminex Corp.7.20. RayBiotech, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/cjcawv

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Read the original:
Outlook on the Microarray Global Market to 2027 - by Type, Application and Region - PRNewswire

CIOs’ 5-year plans for precision medicine and emerging technologies – Healthcare IT News

One of the next big shifts in patient care will be precision medicine will be"an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment and lifestyle for each person," as the Precision Medicine Initiative describes it.

For physicians and researchersthis means predicting more accurately which treatment and prevention strategies for a particular disease will work in particular groups of people.

This is completely different from the traditional one-size-fits-all approach, in which treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.

What does this mean for healthcare and health IT? A lot of new challenges. Because precision medicine and genomics generate massive volumes of varied and granular data, new approaches to data storage and exchangeand new designs for electronic health records,for example, may be required. Physician education and patient communication are two other areas that will demand attention

Some advanced healthcare provider organizations, such as large academic medical centers,are already well-advanced in their precision medicine efforts. But most providers are still early in the journey, if they're attempting it at all. But many are preparing today for what many think will be the next step in the evolution of healthcare.

This story, focused on precision medicine and other emerging technologies, is the sixth and final installment in Healthcare IT News' feature series, "Health IT Investment: The Next Five Years."

The series offers interviews with primarily CIOs to learn from them the path forward through the priorities they set with their investments in six categories: AI and machine learning; interoperability; telehealth, connected health and remote patient monitoring; cybersecurity; electronic health records and population health; and precision medicine and other emerging technologies. Click here to access all the features.

The six health IT leaders discussing their plans for the next five years in this sixth and final installment in the series include:

Precision medicine has been an organizational priority for UPMC for more than a decade, and it has an ambitious vision of using it to provide better, more personalized care and improved outcomes for patients.

"Through these efforts, we aim to create new insights into the drivers of health and disease to allow the discovery of innovative therapies and models of care, while also lowering the cost of care by avoiding diagnostic delays and therapeutic dead ends," said Kleinz of UPMC.

"As one of the largest integrated healthcare delivery and insurance organizations, UPMC has the scale, capabilities and ambition to lead the discovery, assessment and clinical deployment of impactful precision medicine approaches," he continued.

Dr. Matthias J. Kleinz, UPMC Enterprises

"Our efforts are led by the Institute for Precision Medicine, which was established in 2014 in collaboration with our academic research partner, the University of Pittsburgh."

The mission for the institute is to accelerate translational and clinical research in precision medicine and to deliver the most advanced prediction and treatment of disease, tailored to an individual's unique circumstances, history and condition.

"In this context, we have and will continue to make significant investments in established molecular and genomic tests [and]emerging proteomic, metabolomic, and microbiome assay technology, and drive the discovery of highly personalized precision therapeutic approaches, including cell, gene and regenerative medicines," Kleinz explained.

Investment in deployment and development of novel technologies is an important pillar inunlocking the value of precision medicine.

UPMC has made a number of significant initial investments in the following areas, Kleinz noted, and is continuing to evaluate new opportunities:

"UPMC's leadership strongly supports this vision and already has invested heavily in the implementation of precision medicine," he said. "The appropriate use of precision medicine approaches benefits first and foremost our patients, but also supports our providers as they deliver care across the UPMC system.

"The tangible benefits are streamlined clinical workflows, improved patient outcomes, and the potential to optimize resource allocation and reduce the long-term cost of care," he continued.

"We are dedicated to continuing the aggressive rollout of precision medicine, both through internal efforts and increasingly through creative partnerships with industry, such as our partnership with proteomics company Somalogic."

Sanford Health believes precision medicine will be the future of healthcare, so it continues to make significant investments in this space.

"Leveraging machine learning and high computational power to analyze data sets containing genetic, clinical and socioeconomic data will not only help design the best personalized treatment for our patients, but also will help identify those patients or patient populations that would benefit most from early screening and interventions to prevent disease," said Hocks of Sanford Health.

Matt Hocks, Sanford Health

"Precision medicine will allow us to concentrate our efforts on prevention and early screening, diagnosis, and care that will help keep our patients healthy and thriving for generations to come," he added. "Cancer care and chronic disease management are burdensome to patients, communities and health systems. Concentrating resources to prevent these conditions will benefit us all."

Mobile health is an area of health IT that has been emerging in recent years. The same with remote patient monitoring, which has especially gained ground during the COVID-19 pandemic. Virginia Hospital Center is on top of both.

"Virginia Hospital Center does not view itself as cutting-edge when it comes to technology," Mistretta said. "It considers itself more of a fast, early adopter of new technology it believes may provide an advantage to its patients.

"We are extremely patient-focused, so many of our investments moving forward are going to be in that realm," he continued. "We will be investing in hospital-at-home and remote patient monitoring features in depth, along with other patient engagement functions to empower our population and maintain low-touch care to minimize costs."

Mike Mistretta, Virginia Hospital Center

Mobility is in demand by patients, so connecting through web and app technologies will be a high priority, he added.

"We need to make care convenient for patients and provide care on their terms," he observed. "In our Northern Virginia/D.C. market, we hear about this frequently due to traffic and distance considerations."

Thus the development of pilot programs like the organization's OB Connect, where patients followed for maternity care are issued home equipment, post resultsand are able to skip the office if everything is within expected limits. Mistretta believes this kind of technology will permeate the market.

"These types of technologies will be required to sustain significant growth for health systems," he said. "Combined with the effective use of data to produce appropriate metrics, we should be able to pinpoint more specific markets and what treatments produce more effective outcomes.

"It also is the only way we will be able to meet the significant demands that will be placed on the care system with the shortage of nursing and primary care resources predicted to hit in the coming years," he added. "We simply will not be able to continue to experience the same results and levels of treatment enjoyed today as the population grows and ages without providing increased care outside the walls of our traditional organizational structures."

Leadership buy-in on a different approach will take some time, but with successes along the way (and supporting data to reinforce), healthcare organizations will be able to achieve what will be needed, he said.

Providence pledged to invest $50 million over five years in health equity. Here is a recap of how it invested in year one.

Elsewhere, Moore is concerned with the internet of things.

"The internet of things is it it's smart devices," he said. "We may give our patients smart devices that sit in our care delivery environments, and have the telemetry information, and go into our big data model. Because that's how we're really going to make these machine learning and artificial intelligence models shine.

B.J. Moore, Providence

"We in healthcare say big data, but until you're working with streams of data, it's not really big data, it's just large data warehouses," he continued. "So getting that remote care delivery data is important, like a temperature four times a day, or real-time streaming of oxygen or heart data."

Moore believes the IoT and the streams of data it can provide are things healthcare executives should be talking about more. "It's all about data volumes: The bigger the volume, the better," he said.

Regenstrief is in the process of developing tools and processes to identify bias in algorithms to improve health equity, said Grannis of Regenstrief Institute.

"As AI becomes more ubiquitous, researchers, clinicians, health systems, industry, government and others must be wary of unintended consequences," he stated. "Our research scientists are working on best practices as well as novel analytical tools to regularly monitor for bias in algorithms, a process Regenstrief and CEO Dr. Peter Emb have coined "algorithmovigilance."

"Over the next five years, Regenstrief will be working with individuals and organizations around the world to implement," he added.

Dr. Shaun Grannis, Regenstrief Institute

Regenstrief also is investing in the broader ecosystem required to sustain advanced AI and machine learning methods. In the same way that clinical decision-makers, including physicians and other care providers, undergo regular training updates and certification due to healthcare's evolving nature and potential for bias, advanced algorithms will need frequent updates and certification to minimize bias and or errors, Grannis said.

Frameworks for overseeing algorithms and analytics are nascent.Developing and evaluating approaches to accurately and efficiently monitor AI and machine learning will become increasingly important in the future of healthcare analytics, he added.

"We also are investing in patient ergonomics the application of human factors,engineering and psychology to the design and evaluation of patient-facing technology to enhance delivery of healthcare," he explained.

"Institute scientists are using user-centered design to create apps that help informal caregivers provide care for their loved ones with Alzheimer's and other chronic conditions. Other apps are exploring the benefits of specific diets and brain-stimulating games."

Babachicos of South Shore Health believes tools that assist patients with care navigation will allow for a more improved and directed patient experience.

"These tools combined with the next-generation call centers also known as patient access centers can be accessed 24/7 by patients looking for care options and direct patients to the right place at the right time for their care needs," she explained. "These patient access centers will use multichannel options such as text, voice and chat while allowing patients to perform many self-service functions, as well.

Cara Babachicos, South Shore Health

"These patient access centers might also be staffed by care navigators for a more human connection when necessary," she concluded. "The same centers could potentially deliver virtual visits/consults, as well as potentially manage patient medications and vitals for subscribed patients in the community."

Twitter:@SiwickiHealthITEmail the writer:bsiwicki@himss.orgHealthcare IT News is a HIMSS Media publication.

Link:
CIOs' 5-year plans for precision medicine and emerging technologies - Healthcare IT News

Molecular Diagnostic Market 2021 Opportunity And Competitive Landscape Forecast to 2028 The Oxford Spokesman – The Oxford Spokesman

Global Molecular Diagnostic Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis. It also provides market information in terms of development and its capacities.

MR Accuracy Reports crafted the report, titled Global Molecular Diagnostic Market 2021 is a methodical research study based on the Molecular Diagnostic Market, analyzing the competitive framework of the industry in the world. Using efficient analytical tools such as SWOT analysis and Porters five forces analysis, the report provides a comprehensive assessment of the Molecular Diagnostic Market. Our big research team were able to captured all-important chapters in the final report as they have been striving towards it.

Download Free PDF Sample Reportwith Complete TOC and Figures & Graphs (withcovid 19Impact Analysis):https://www.mraccuracyreports.com/report-sample/499394

Molecular diagnostics is growing rapidly. Molecular diagnostic tests detect specific sequences in DNA or RNA that may or may not be associated with disease, including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions and others. Clinical applications can be found in at least six general areas: infectious diseases; oncology; pharmacogenomics; genetic disease screening; human leukocyte antigen typing; and coagulation.

The report forecast global Molecular Diagnostic market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021E-2026F due to coronavirus situation.

The report offers detailed coverage of Molecular Diagnostic industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Molecular Diagnostic by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

First, this report covers the present status and the future prospects of the global Molecular Diagnostic market for 2016-2025.

And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

At the same time, we classify Molecular Diagnostic according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Finally, the report provides detailed profile and data information analysis of leading Molecular Diagnostic company.

Key Content of Chapters as follows (Including and can be customized) :

Part 1:

Market Overview, Development, and Segment by Type, Application & Region

Part 2:

Company information, Sales, Cost, Margin etc.

Part 3:

Global Market by company, Type, Application & Geography

Part 4:

Asia-Pacific Market by Type, Application & Geography

Part 5:

Europe Market by Type, Application & Geography

Part 6:

North America Market by Type, Application & Geography

Part 7:

South America Market by Type, Application & Geography

Part 8:

Middle East & Africa Market by Type, Application & Geography

Part 9:

Market Features

Part 10:

Investment Opportunity

Part 11:

Conclusion

Market Segment as follows:

By Region

Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]

Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

North America[United States, Canada, Mexico]

Middle East & Africa[GCC, North Africa, South Africa]

South America[Brazil, Argentina, Columbia, Chile, Peru]

Key Companies

Roche

Abbott

Gen-Probe

Danaher

Thermo Fisher

Siemens

Qiagen

BD

Biomerieux

GE

Market by Type

PCR instrument

ISH instrument

Gene chip matching Equipment

Market by Application

Prenatal

Infectious disease

Cancer

Others

GetExclusive Discount on this report:https://www.mraccuracyreports.com/check-discount/499394

Key questions answered in the report include:

If you have any special requirements, please let us know and we will offer you the report as you want

You can buy the complete report@ https://www.mraccuracyreports.com/checkout/499394

About Us:

MR Accuracy Reports well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future. Our research reports arm our clients with macro-level insights across various key global regions that equip them with a broader perspective to align their strategies to capitalize on lucrative growth opportunities in the market.

Contact Us:MR Accuracy Reports,USA: +1 804 500 1224UK: +44 741841 3666 ASIA: +91 747888728100Email: sales@mraccuracyreports.com Website: https://www.mraccuracyreports.com

Originally posted here:
Molecular Diagnostic Market 2021 Opportunity And Competitive Landscape Forecast to 2028 The Oxford Spokesman - The Oxford Spokesman

Immuno In-Vitro Diagnostics (IVD) Market 2022 Growth, Segments, Industry by Size, Share, Demand, Trends and Top Companies Overview to 2029 | F….

The World Class Immuno In-Vitro Diagnostics (IVD) Market Research Report makes knowledgeable about the Immuno In-Vitro Diagnostics (IVD) industry and competitive landscape which supports enhanced decision making, better manage marketing of goods and decide market goals for better profitability. Immuno In-Vitro Diagnostics (IVD) market report has been structured after a thorough study of various key market segments like market size, share, growth, demand, latest trends, market threats and key drivers which drives the market. All the statistical data and information involved in this marketing report is characterized properly by using several charts, graphs or tables. The report provides strategically analyzed market research analysis and observant business insights into the most relevant markets of our clients. The winning Immuno In-Vitro Diagnostics (IVD) market research report helps clients recognize new opportunities and most important customers for their business growth and increased revenue.

Immuno In-Vitro Diagnostics (IVD) Market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to account to USD 23.97 billion by 2029 and will grow at a CAGR of 4.78% in the above mentioned forecast period.

Download Free Exclusive Sample (350 Pages PDF) Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-immuno-ivd-market

The Immuno In-Vitro Diagnostics (IVD) Market 2022 report brings into focus studies about market definitions, classifications, applications and industry chain structure. Immuno In-Vitro Diagnostics (IVD) Market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Third by regions, this report focuses on the sales (consumption), production, import and export of Immuno In-Vitro Diagnostics (IVD) in United States, Europe, China, Japan, and Southeast Asia, India.

On the basis of report- titled segments and sub-segment of the market are highlighted below:

ByProduct Type (Reagents, Instruments, Data Management Software, Services) Immunodiagnostics Technique (Enzyme-Linked Immunosorbent Assay, Rapid Tests, Enzyme-Linked ImmunoSpot Assays, Radioimmunoassay, Western Blotting)

By Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Drug Testing/Pharmacogenomics, HIV/AIDS, Autoimmune Diseases, Nephrology, Others)

By End User (Hospital Laboratories, Clinical Laboratories, Point Of Care Testing, Patient Self-Testing, Academic Institutes, Others)

List of Significant Vendors Operating in this market include:

Global Immuno In-Vitro Diagnostics (IVD) Market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and instrumentation and downstream demand analysis is additionally dispensed. The Global Immuno In-Vitro Diagnostics (IVD) market development trends and marketing channels are analyzed. Finally, the feasibility of latest investment projects is assessed and overall analysis conclusions offered.

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @ https://www.databridgemarketresearch.com/toc/?dbmr=global-immuno-ivd-market

Global Immuno In-Vitro Diagnostics (IVD) Market Scenario

Immuno in-vitro diagnostics test are generally performed on blood or tissue samples to identify disease or any serious condition. These devices have next generation sequencing tests which can help them to sense genomic variation in person DNA.

The increasing geriatric population and high growth in the prevalence of chronic and infectious diseases is amongst the important factors intensifying the growth and demand of immuno in-vitro diagnostics (IVD) market. In addition, the high adoption of fully automated and POC instruments in emerging regions and increasing geriatric population are also contributing to the growth in the global market over the forecast period of 2021 to 2028. Also the rising awareness regarding disease diagnosis and increasing R&D investments by industry players to launch new IVD products are also enhancing the growth of the market. Furthermore, the higher disposable income and expansion of automated in vitro diagnostic systems for laboratories and hospitals to give resourceful, precise and error-free diagnosis are also one of the significant factors fueling the growth of the immuno in-vitro diagnostics (IVD) market. Increases vulnerability to acquiring various diseaseswill also make sure high industry growth over the forecast period.

Global Immuno In-Vitro Diagnostics (IVD) Market Scope and Market Size

Immuno in-vitro diagnostics (IVD) market is segmented on the basis of product type, immunodiagnostics technique, application and end user. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of product type, the immuno in-vitro diagnostics (IVD) market is segmented into reagents, instruments, data management software and services. Instruments have further been segmented into semi-automated instruments, fully automated instruments and other instruments.

Immuno in-vitro diagnostics (IVD) market is also segmented on the basis of immunodiagnostics technique into enzyme-linked immunosorbent assay, rapid tests, enzyme-linked immunospot assays, radioimmunoassay and western blotting. Enzyme-linked immunosorbent assay have further been segmented into chemiluminescence immunoassays, fluorescence immunoassays and colorimetric immunoassays.

Based on application, the immuno in-vitro diagnostics (IVD) market is segmented into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology and others.

The end user segment of immuno in-vitro diagnostics (IVD) market is segmented into hospital laboratories, clinical laboratories, point of care testing, patient self-testing, academic institutes and others. Clinical laboratories have further been segmented into large/reference laboratories, medium-sized laboratories and small laboratories.

For stakeholders and business professional for expanding their position in the Immuno In-Vitro Diagnostics (IVD) Market:

Q 1. Which Region offers the most rewarding open doors for the market Ahead of 2022?

Q 2. What are the business threats and Impact of COVID scenario Over the market Growth and Estimation?

Q 3. What are probably the most encouraging, high-development scenarios for Immuno In-Vitro Diagnostics (IVD) movement showcase by applications, types and regions?

Q 4.What segments grab most noteworthy attention in Immuno In-Vitro Diagnostics (IVD) Market in 2022 and beyond?

Q 5. Who are the significant players confronting and developing in Immuno In-Vitro Diagnostics (IVD) Market? Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2029) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:o North America (Covered in Chapter 6 and 13)o Europe (Covered in Chapter 7 and 13)o Asia-Pacific (Covered in Chapter 8 and 13)o Middle East and Africa (Covered in Chapter 9 and 13)o South America (Covered in Chapter 10 and 13)

For More Information or Query or Customization Before Buying, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-immuno-ivd-market

With tables and figures helping analyses worldwide Global Immuno In-Vitro Diagnostics (IVD) market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Immuno In-Vitro Diagnostics (IVD) Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Immuno In-Vitro Diagnostics (IVD) Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Immuno In-Vitro Diagnostics (IVD) Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Immuno In-Vitro Diagnostics (IVD) Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Immuno In-Vitro Diagnostics (IVD) Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Immuno In-Vitro Diagnostics (IVD) Market.

Market Forecast:Here, the report offers a complete forecast of the global Immuno In-Vitro Diagnostics (IVD) Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Browse Complete Report Details@https://www.databridgemarketresearch.com/reports/global-immuno-ivd-market

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

Top Related Report from DBMR:

Anorexiants Market 2022 by Size Estimation, Demand, Trends, Market Dynamics, Competition by Manufacturers-Bausch Health, Virtus, Lannett, Sun Pharmaceutical

Diabetic Macular Edema (DME) Market Size, Share, Trends 2022, Demand, Growth, Development| F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc

Antacids Market Size, Share, Growth, Industry Overview, New Opportunities & SWOT Analysis by 2029| Top Key Players: Perrigo Company plc, Johnson & Johnson Services, Salix Pharmaceuticals

Cancer Monoclonal Antibodies Market 2022 Growth, Segments, Industry by Size, Share, Demand, Trends and Top Companies Overview to 2029| Abbvie, Pfizer, Amgen, Novartis AG

Gastritis Market 2022 Global Industry Size, Demand, Growth Analysis, Share, Revenue and Forecast 2029

Acetaminophen (Paracetamol) Market Share, Size- 2022 Industry Trends, Progress Insight, Developing Technologies, Competitive, Regional, And Global Industry Forecast to 2029

Laxative Market 2022 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key Country Forecast to 2029

Electrostatic Disinfectant Sprayer Industry 2022 Global Market Size, Growth, Share, Emerging Demand, Current Trends, Company Profiles, Competitive Landscape and Forecasts till 2029

Care Management Solutions Market 2022 Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2029

Artificial Intelligence (AI) In Drug Discovery Market 2022 Industry Demand, Share, Statistics, Global Trend, Top Key Players Update and Forecast to 2029

Hospital Electronic Medical Records (EMR) Systems Market 2022 Global Industry Size, Share, Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2029

Why Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delves into the markets across Asia, North America, South America, and Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

E-Mail:Corporatsesales@databridgemarketresearch.com

See the original post:
Immuno In-Vitro Diagnostics (IVD) Market 2022 Growth, Segments, Industry by Size, Share, Demand, Trends and Top Companies Overview to 2029 | F....

Reducing Heterogeneity in NonTreatment-Resistant and Treatment-Resistant Schizophrenia – Psychiatric Times

SPECIAL REPORT: TREATMENT RESISTANCE

Schizophrenia affects about 1% of the population and causes a tremendous burden on patients and families.1 Patients with schizophrenia present with diverse symptoms (ie, positive, negative, and cognitive), and the course and response to treatment varies widely. The basis of this heterogeneity is unknown but presumably results from a complex interaction of multiple genetic and environmental factors. To establish more homogeneous subpopulations, efforts have been made to use subtype based on clinical presentation or response to treatment, or by biomarkers derived from imaging, omics, or postmortem pathology (Figure). Due to the heterogeneity, subtyping approaches hold promise and should be considered when designing studies.

Definition of Response Subtypes

About 70% of patients respond at least reasonably well to treatment with standard antipsychotics (plus psychosocial interventions), and hence are considered to have nontreatment-resistant schizophrenia (non-TRS). However, up to 30% of patients do not respond to standard antipsychotic treatment and are therefore considered to have TRS, generally defined as a failed response to 2 full trials of conventional antipsychotics (see Treatment Response and Resistance in Psychosis [TRRIP] guidelines2 for more details). The only US Food and Drug Administration (FDA)-approved medicine for TRS is clozapine3; however, about 30% of TRS patients do not respond to clozapine and are considered to have ultra-TRS (UTRS).4 Currently, these definitions refer mainly to improvement in positive symptoms, reflecting the greater efficacy of available antipsychotics for treating positive symptoms compared to negative and cognitive symptoms. TRS (grouped together with UTRS in most studies) may derive from a more severe version of the same underlying pathophysiology as non-TRS. However, it is possible that TRS may be a distinct subtype of the illness with a different pathophysiology than non-TRS.5,6

Clinical Features

Analysis of clinical phenotype suggests that patients with TRS have an earlier age of onset than patients with non-TRS.7,8 Unlike non-TRS, the ratio of men to women with TRS is equal,7,8 although the extent to which this reflects a biological difference between non-TRS and TRS rather than the interaction of gender roles and age of disease onset remains to be determined. At the time of first diagnosis, patients who eventually develop TRS are more likely than future non-TRS patients to be inpatients, to require moremedicine, and to spend more than 30days in a psychiatric hospital.8 Cognitive functioning, and particularly verbal memory, is more impaired in patients with TRS than with non-TRS.9,10 TRS may also be more familial than non-TRS; first- and second-degree relatives of patients with TRS have an increased risk of developing schizophrenia compared with relatives of patients with non-TRS.11 The extent to which positive, negative, and cognitive symptoms associate with this different pattern of inheritance remains unclear.

Neurobiological Features

To understand the neurobiology of TRS, investigations have taken 2 general approaches. One is to determine the genetics of clozapine response, and the second is to identify genes and biological pathways most relevant to TRS. Initial pharmacogenetic studies of clozapine took a candidate gene approach and tended to focus on the major neurotransmitter systems implicated in the pharmacodynamics of clozapine and other antipsychotics. Response to clozapine was preliminarily associated with genetic markers linked to dopamine and serotonin receptors.12 However, these findings have not been consistently replicated, possibly due to variation in the criteria used to select subjects, inconsistencies in the definition of TRS, and ethnic differences among the populations under investigation, all in the context of small effect sizes.

Unbiased, noncandidate approaches to the neurobiology of schizophrenia provide an opportunity to identify novel pathogenic pathways. Because developing new antipsychotics based on fine-tuning the neurotransmitter profile of previously developed antipsychotics has not led to marked breakthroughs in clinical efficacy, this new approach is of critical importance. This is reflected in more recent pharmacogenomic approaches, using genome-wide association studies (GWAS) instead of data limited to markers associated with prespecified candidate genes. Findings suggest that patients with TRS, compared with patients with non-TRS, have higher polygenetic risk scores (an index of overall genetic risk of developing a disease),13 a higher frequency of disruptive mutations,14 and higher rates of chromosomal duplications and deletions.15 This approach has found an association between specific genomic loci and TRS including inter-alpha-trypsin inhibitor heavy chain 3/4 (ITIH3/4); calcium voltage-gated channel subunit alpha1 C (CACNA1C); and serologically defined colon cancer antigen 8 (SDCCAG8).16 Many of these studies have not yet been replicated, again likely a consequence small sample size, inconsistent inclusion criteria, and varying definitions of TRS.

As an alternative approach to pharmacogenomic studies of clozapine using GWAS, our laboratory examined gene expression in autopsied human brains from individuals with TRS (on clozapine at time of death) and non-TRS (on conventional antipsychotics at time of death).17 A number of specific genes were differently expressed, including the genes glutamate-cysteine ligase modifier subunit (GCLM), zinc finger protein 652 (ZNF652), and glycophorin C (GYPC). Pathways associated with TRS included clathrin-mediatedendocytosis, stress-activated protein kinase/c-Jun-terminal kinase signaling, 3-phosphoinositide synthesis, and paxillin signaling, each providing potential leads in the search for new therapeutic targets.

Imaging Features

Imaging studies show relative frontal and temporal grey matter volume deficits in TRS,18-21 possible white matter tract disruption,22 and disruptions of functional connectivity, particularly in frontotemporal networks, with direct and indirect involvement of the thalamus.23-25 Perfusion measured by single-photon emission computerized tomography (SPECT) appears to be reduced in multiple brain regions in TRS and is partially corrected by clozapine; clinical improvement correlates with improved perfusion in the thalamus.18,26,27

Further, treatment-resistant hallucinations correlated with increased cerebral blood flow measured by arterial spin label MRI in the temporal-parietal cortex.28 (18)F-FDOPA positron emission tomography studies detected higher striatal DA synthesis capacity in patients with non-TRS than in those with TRS and healthy control (HC) individuals, but no difference in DA synthesis capacity between TRS and HC.29 Elevatedglutamateconcentration in the anteriorcingulate cortexwas identified in the patients with TRS compared with non-TRS and HC,30 a finding that was subsequently replicated.31 The utility of these measures for determining which patients should receive clozapine remains to be determined.

Differentiating UTRS and TRS

To date, few studies separate TRS from UTRS, which is potentially a serious impediment to defining disease neurobiology, as these 2 forms of TRS may be pathologically and pathophysiologically distinct. The findings of the few studies that have directly compared TRS with UTRS, or UTRS with HC, are listed in Table 1. It is likely that these are fundamental to the illness and not a factor of disease progression because the majority of patients who develop TRS do so from the onset of symptoms,39and the majority of patients with UTRS show limited improvement from the beginning of treatment with clozapine. So far, these findings remain preliminary and await replication. Using biochemical techniques, our laboratory has recently demonstrated increased protein insolubility, and potentially protein aggregation, in a subset of autopsied brains of individuals with schizophrenia.40 It is possible that this phenomenon, or related pathophysiological processes, may distinguish among non-TRS, TRS, and UTRS.

We performed a cross-sectional study to determine if there are differences in symptoms, cognitive functioning, or real-world functional capacity that distinguish UTRS from TRS.41 Patients who responded to clozapine performed significantly better on a validated assessment tool of function, developed by Philip Harvey, PhD, and colleagues, consisting of computer simulations of banking at an ATM, purchasing a ticket, and obtaining a prescription refill, and on overall cognition as assessed by the Brief Assessment of Cognition in Schizophrenia. The cross-sectional design did not allow us to determine if patients who eventually responded to clozapine were as impaired as eventual nonresponders but improved on clozapine, or if they were less functionally impaired at the outset of clozapine treatment. This last question will be addressed in a longitudinal study of individuals beginning treatment with clozapine.

This study highlights the potential confounding of grouping UTRS with TRS in studies of disease phenotype, pathogenesis, and treatment response. It is possible, for instance, that someor allof the genetic and neurobiological differences reported between non-TRS and TRS is in fact driven by UTRS. Furthermore, our work on protein homeostasis abnormalities and protein insolubility suggests that pathological processes can be identified in a subtype of patients with clinical correlations subsequently determined and eventually, specific treatments designed (Figure).40 Taken together, the available data suggests that subtyping based on treatment response is a plausible approach to understanding the heterogenous pathophysiological mechanisms related to schizophrenia. This is somewhat analogous to the past recognition that subtypes of psychotic syndromes that strongly resemble idiopathic schizophrenia could be explained by infections (eg, syphilis), nutritional deficiency (eg, niacin), or substances (eg, chronic amphetamine abuse).

Historically, this type of reasoning has led to advances and specific treatments, as specific causes of psychotic syndromesincluding syphilis, niacin deficiency, and chronic amphetamine abusewere identified. TRS is one way to subtype patients, but other approaches using variability in physiological parameters, such as the Bipolar and Schizophrenia Network for Intermediate Phenotypes (BSNIP), or protein homeostats abnormalities, as we have shown, are other ways that this problem could be addressed.

Recommendations for Treatment

Although clozapine has been clearly established as the treatment of choice for individuals with schizophrenia who do not respond to 2 trials of a standard antipsychotic, or who have other specific indications, it is vastly underused. Based on the rate of treatment failure of conventional antipsychotics, the indication of clozapine for reducing the risk of suicide, the relatively low risk of neurological disorders with clozapine, and the potential value of the drug in ameliorating schizophrenia symptoms such as polydipsia, between 30% and 40% of US patients with schizophrenia should be receiving clozapine, whereas the actual rate is approximately 4%.42 Even for those receiving clozapine, the average delay from the point in time when clozapine would have been considered indicated is 48 months.43 Patients who might respond to clozapine are instead treated with multiple antipsychotics or high-dose antipsychotics. The underuse is likely a consequence of strict guidelines for prescribing clozapine that burden both clinicians and patients, and fear of adverse effects on the part of patient, family, and clinicians.

Unfortunately, our current understanding of the neurobiology of TRS and UTRS is insufficient to predict who will respond to clozapine and who will develop adverse effects. Delay in initiating clozapine treatment is associated with poorer outcomes, and potentially with adverse effects from exposure to excess doses of ineffective medicines. Clozapine adverse effects can be monitored and mitigated, and data suggest that patients are less bothered by mandatory blood draws than prescribers tend to think and prefer clozapine to other medications.44-46

There are a number of resources to help prescribers wishing to use clozapine (Table 2). Expanding these programs and seeking advice from established clozapine clinics, such as the one we have at Johns Hopkins, and others across the country could provide instruction and consultation. Improving the ease of use of the agent and relaxing some of the Clozapine Risk Evaluation and Mitigation Strategy registry restrictions could help address the underutilization of clozapine.

Concluding Thoughts

These data suggest that subtyping patients based on treatment response (TRS or UTRS versus non-TRS) could identify more homogeneous populations of patients with distinct differences in pathophysiology. Understanding the mechanisms leading to TRS and UTRS, and the difference between the 2, may provide the opportunity to develop biomarkers of disease state and treatment response, and to develop novel treatments. Further, the available data suggests that genetic, clinical, and pathogenic studies will benefit by considering treatment response as a variable. Finally, patients with schizophrenia who do not respond well to treatment suffer considerably and place great stress on their families and the health care system. Investment in research and services for this group of patients is imperative.

Dr Nucifora is an associate professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine in Baltimore, Maryland.

References

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia.PLoS Med. 2005;2(5):e141.

2. Howes OD, McCutcheon R,Agid O,et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry.2017;174(3):216-229.

3. Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development.Neurotherapeutics. 2017;14(3):750-761.

4. Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis.Can J Psychiatry. 2017;62(11):772-777.

5. Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.BMC Psychiatry. 2017;17(1):12.

6. Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives.Neurobiol Dis. 2019;131:104257.

7. Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Findling RL, Thompson PA. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.Am J Psychiatry. 1997;154(4):475-482.

8. Wimberley T, Stvring H, Srensen HJ, et al. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry. 2016;3(4):358-366. Published correction appears in Lancet Psychiatry. 2016;3(4):320.

9. Joober R, Rouleau GA, Lal S, et al. Neuropsychological impairments in neuroleptic-responder vs -nonresponder schizophrenic patients and healthy volunteers.Schizophr Res. 2002;53(3):229-238.

10. de Bartolomeis A, Balletta R, Giordano S, et al. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.Psychiatry Res. 2013;210(2):387-395.

11. Joober R, Rouleau GA, Lal S, et al. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients.Schizophr Res. 2005;77(1):35-41.

12. Sriretnakumar V, Huang E, Mller DJ. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.Expert Opin Drug Metab Toxicol. 2015;11(11):1709-1731.

13. Frank J, Lang M, Witt SH, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients.Mol Psychiatry. 2015;20(7):913.

14. Ruderfer DM, Charney AW, Readhead B, Kidd BA. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.Lancet Psychiatry. 2016;3(4):350-357.

15. Martin AK, Mowry B. Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia.Psychol Med. 2016;46(3):469-476.

16. Hamshere ML, Walters JT, Smith R, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol Psychiatry. 2013;18(6):708-712. Published correction appears in Mol Psychiatry. 2013;18(6):738.

17. Lee BJ, Marchionni L, Andrews CE, et al. Analysis of differential gene expression mediated by clozapine in human postmortem brains.Schizophr Res. 2017;185:58-66.

18. Molina V, Tamayo P, Montes C, et al. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients.Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(4):948-954.

19. Anderson VM, Goldstein ME, Kydd RR, Russell BR. Extensive gray matter volume reduction in treatment-resistant schizophrenia.Int J Neuropsychopharmacol. 2015;18(7):pyv016.

20. Quarantelli M, Palladino O, Prinster A, Schiavone V. Patients with poor response to antipsychotics have a more severe pattern of frontal atrophy: a voxel-based morphometry study of treatment resistance in schizophrenia.Biomed Res Int. 2014;2014:325052.

21. Maller JJ, Daskalakis ZJ, Thomson RH, Daigle M, Barr MS, Fitzgerald PB. Hippocampal volumetrics in treatment-resistant depression and schizophrenia: the devils in de-tail.Hippocampus. 2012;22(1):9-16.

22. Holleran L, Ahmed M, Anderson-Schmidt H, et al. Altered interhemispheric and temporal lobe white matter microstructural organization in severe chronic schizophrenia.Neuropsychopharmacology. 2014;39(4):944-954.

23. Wolf ND, Sambataro F, Vasic N, et al. Dysconnectivity of multiple resting-state networks in patients with schizophrenia who have persistent auditory verbal hallucinations.J Psychiatry Neurosci. 2011;36(6):366-374.

24. Vercammen A, Knegtering H, den Boer JA, Liemburg EJ, Aleman A. Auditory hallucinations in schizophrenia are associated with reduced functional connectivity of the temporo-parietal area.Biol Psychiatry. 2010;67(10):912-918.

25. Alonso-Sols A, Vives-Gilabert Y, Grasa E, et al. Resting-state functional connectivity alterations in the default network of schizophrenia patients with persistent auditory verbal hallucinations.Schizophr Res. 2015;161(2-3):261-268.

26. Molina Rodrguez V, Montz Andre R, Prez Castejn MJ, et al. Cerebral perfusion correlates of negative symptomatology and parkinsonism in a sample of treatment-refractory schizophrenics: an exploratory 99mTc-HMPAO SPET study.Schizophr Res. 1997;25(1):11-20.

27. Molina V, Gispert JD, Reig S, et al. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement.Psychopharmacology (Berl). 2005;178(1):17-26.

28. Wolf ND, Grn G, Sambataro F, et al. Magnetic resonance perfusion imaging of auditory verbal hallucinations in patients with schizophrenia.Schizophr Res. 2012;134(2-3):285-287.

29. Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.Am J Psychiatry. 2012;169(11):1203-1210.

30. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.Biol Psychiatry. 2014;75(5):e11-e13.

31. Mouchlianitis E, Bloomfield MAP, Law V, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive.Schizophr Bull. 2016;42(3):744-752.

32. Griffiths K, Millgate E, Egerton A, MacCabe JH. Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis.Psychol Med. 2021;51(3):376-386.

33. Molina Rodrguez V, Montz Andre R, Prez Castejn MJ, et al. SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine.Am J Psychiatry. 1996;153(10):1343-1346.

34. Goldstein ME, Anderson VM, Pillai A, et al. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia.Int J Neuropsychopharmacol. 2015;18(6):pyu117.

35. Iwata Y, Nakajima S, Plitman E, et al. Glutamatergic neurometabolite levels in patients with ultra-treatment-resistant schizophrenia: a cross-sectional 3T proton magnetic resonance spectroscopy study.Biol Psychiatry. 2019;85(7):596-605.

36. McNabb CB, Tait RJ, McIlwain ME, et al. Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia.Schizophr Res. 2018;195:160-167.

37. Fond G, Godin O, Boyer L, et al; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group. Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort.Eur Arch Psychiatry Clin Neurosci. 2019;269(8):985-992.

38. Kim J, Plitman E, Iwata Y, et al. Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders.Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109839.

39. Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors.Psychol Med. 2017;47:1981-1989.

40. Nucifora LG, MacDonald ML, Lee BJ, et al. Increased protein insolubility in brains from a subset of patients with schizophrenia.Am J Psychiatry. 2019;176(9):730-743.

41. Nucifora FC Jr, Baker KK, Stricklin A, et al. Better functional capacity and cognitive performance in clozapine responders compared to non-responders: a cross-sectional study.Schizophr Res. 2021;229:134-136.

42. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy.Clin Schizophr Relat Psychoses. 2012;6(3):134-144.

43. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation.Br J Psychiatry. 2012;201(6):481-485.

44. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists attitude towards and knowledge of clozapine treatment.J Psychopharmacol. 2010;24(7):965-971.

45. Hodge K, Jespersen S. Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians.Int J Ment Health Nurs. 2008;17(1):2-8.

46. Taylor DM, Shapland L, Laverick G, Bond J, Munro J. Clozapine a survey of patient perceptions. Psychiatr Bull. 2000;24(12):450-452.

See the original post:
Reducing Heterogeneity in NonTreatment-Resistant and Treatment-Resistant Schizophrenia - Psychiatric Times